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                                                 INTRODUCTION
Worldwide, cervical cancer comprises 12% of all cancers in women and 2,31,000 women die of 
cervical cancer every year, over 80% of whom live in developing countries. South east Asia contributes 
about 25% of the total disease burden.
Cervical cancer is the most common genital tract cancer in Indian women with 1,26,000 new 
cases and 70,000 deaths each year. Incidence is higher than in Eastern Asia. Across India cervical 
cancer is the commonest cancer reported from all cancer registries except those in Mumbai & Delhi 
where breast cancer is the commonest. 
Cervical cancer is a preventable disease because of its long preinvasive state of over 10 to 15 
years, availability of various screening programmes, effective treatment for preinvasive lesions. World 
wide,  successful  cervical  cancer  prevention  is  based  on an organized  screening  program.  Cervical 
cytology is  presently considered to  be the only test  known to reduce cervical  cancer  incidence in 
organized  screening  programs.  The  goal  of  periodic  cervical  cancer  screening  is  to  detect  the 
preinvasive state of the disease and treat it  appropriately before it progresses to cervical cancer. In 
developed countries initiation and sustenance of cervical cytology programs, involving screening of 
sexually active women yearly or once every 2-5 years have resulted in a large decline in cervical cancer 
incidence,  mortality and morbidity there by saving women’s life.  However an organized screening 
program is difficult to implement in developing countries where resources are scarce. 
Community  based  screening  programs  require  a  relatively  sophisticated  infrastructure, 
including  highly  trained  personnel,  adequately equipped  laboratories  and  good  referral  systems  to 
communicate  the  results  of  the  test  to  the  women.  In  view  of  these  requirements,  an  alternative 
screening methods like VIA,VIAM,VILI is needed in developing countries with very limited resources 
and infrastructure because it is inexpensive, requires supplies usually locally obtainable and can be 
competently performed by non physician. 
Prior to the use of pap smear and cytology based screening programs, health care providers 
relied on looking at the cervix to detect abnormalities. After 1950, cytology became the standard for 
cervical  screening  and  the  colposcope  was  used  to  further  investigate  the  cervix.  Unaided  visual 
inspection (down staging) was evaluated by three cross sectional studies in India. Though the accuracy 
of down staging alone  in the early detection of cervical carcinoma and precursor lesions was found to 
be inadequate, a combination of downstaging, VIA, VILI, VIAM as a cancer screening tool was very 
effective.
Pap smear, colposcopy and cervix biopsy are the other methods by which the cervix can be 
studied for the evidence of early malignant disease. These are out patient procedure and requires no 
anaesthesia.
The accuracy of detection and diagnosis may be increased by a systematic combination of the 
above screening procedures.
AIM OF THE STUDY
1. To do cervical cancer screening by VIA and VILI.
2. To determine the sensitivity and specificity of VIA, VILI.
3. To assess the reliability of VIA and VILI as a cancer screening tool in the 
detection of precancerous lesions of cervix by comparing its sensitivity and 
specificity  with  pap  smear   keeping  colposcopy  and  colposcopy  directed 
biopsy as reference standard.  
4. To study the efficacy of combined screening programs.
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MATERIALS AND METHODS
500 patients were selected from the Gynaecology OPD of Government R.S.R.M. 
lying in Hospital Chennai – 13, considering the following criteria.
INCLUSION CRITERIA
1.    Women with history of sexual activity for more than three years with  
       Intact uterus and cervix.
2.    Non pregnant.
3.    No past / present history suggestive of CIN / Cancer cervix.
4.    No bleeding P/V at the time of examination.
5.    Not had any treatment for cervical lesion (like Cryo, cautery,laser  
       etc.)
EXCLUSION CRITERIA
1.   Unmarried woman not exposed to sexual activity.
2.   Pregnant women.
3.   Women who have had therapy for cervical lesion.
4.   Patient in periods / bleeding PV.
5.   Previous colposcopy done.
6.   Prior hysterectomy.
7.   Obvious growth on cervix.
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All  500  women  were  subjected  to  a  questionnaire  addressing  clinical  and 
epidemiological  risk  factors  of  cervical  disease  (eg.  Socio  economic  class,  age  of 
marriage, parity, birth spacing, occupation, travelling jobs etc.). Then all women were 
subjected to down staging, pap smear, VIA,VILI and colposcopy. The decision to take a 
histological specimen was based upon the abnormal colposcopic findings and by grading 
(combined  colposcopic  index).  Normal  cervix  by  colposcopy  was  accepted  as  truly 
normal cervix.
DOWN STAGING
Materials - Sim’s Speculum
Light Source
Sterile gloves
Examination table.
Patient was put in lithotomy position, speculum examination preceded bimanual 
pelvic examination in all cases to prevent.
1. Removal of desquamated epithelium from the surface of cervix.
2. The  lubricant  may  disturb  the  discharge  obtained  for  bacteriological  and 
cytological study.
3. A bleed from surface lesion may prevent inspection.
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PAP SMEAR
Materials
Cusco’s bivalved self retaining speculum
Nulliparous - 28 mm
Postmenopause - 28 mm
Multiparous - 36 mm
Light Source
Ayre’s spatula 
Endo cervical brush
Glass slide
Marker Pencil
Sterile glove
Fixative 95% ethanol / cytofix spray
SAMPLING AND PREPARATION METHODS
Patient Instructions 
1. Schedule the examination, two weeks after the first day of last menstrual period – more 
specifically  it  is  preferable  to  avoid  examination  during  menses  because  blood  may 
obscure significant findings.
2.  Do not use vaginal medication, vaginal contraceptives or douches for 48 hours before 
the appointment. 
3. Intercourse is not recommended the night before the appointment.
11
SPECIMEN COLLECTION
1. Specimen should be obtained after a non-lubricated speculum (moistened only with 
warm water if needed) is inserted, prior to vaginal examination to prevent removal of 
desquamated cervical cells thereby preventing false negative reports
2. Excess mucus or other discharge should be removed gently with ring forceps holding a 
folded gauze pad.
3. Sample should be obtained before the application of acetic acid or Lugol’s iodine.
4. An optimal sample includes cells from the ectocervix and endocervix.
Patient was put in lithotomy position and a suitable sized Cusco’s speculum was 
introduced without  lubricant.  The  cervix  was  visualized  with  good light  source.  The 
cervical smear was taken with an Ayre’s spatula rotating it through 360 degrees over the 
squamo columar junction.  Sample from the endocervix was taken using endocervical 
brush rotated gently only one quarter turn. The smear should be applied and fixed over 
the slide marked with the pap smear number for that patient. Immediate fixation (within 
seconds) is critical  in order to prevent air  drying artifact  which distorts the cells  and 
hinders interpretation. It was then subjected to modified  papanicolaou staining in the 
laboratory and studied. The fixed slides are transferred directly from the fixative into the 
following solutions:
1. 80% ethyl alcohol - 10 dips
2. 70% ethyl alcohol - 10 dips
3. 50% ethyl alcohol - 10 dips
4. Distilled water - 10dips
5. Harris haematoxylin - 3mts.
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6. Running tap water - 1mt.
7. HCl (0.5%) - 5 dips
8. Again running tap water - 1dip
9. 50% ethyl alcohol - 10dips
   10. 70% ethyl alcohol - 10dips
   11. 80% ethyl alcohol - 10dips
   12. 95% ethyl alcohol - 10dips
   13. Orange G6 - 1mt.
   14. 90% ethyl alcohol - 10dips
   15. G.A 36 - 4mts.
   16. 95% ethyl alcohol - 10dips
   17. Absolute alcohol - 10dips
   18. Xylene - 3dips
   19. Clear in Xylol - 3dips
Slides are mounted with DPX.
Results: Nucleus – Blue colour
Cytoplasm of superficial cells – pink
Cytoplasm of  intermediate cells – Bluish green
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VISUAL INSPECTION WITH ACETIC ACID AND LUGOL’S IODINE
Materials
Private examination room
Examination table with stirrups
Good light source (100 Watts lamp)
Sterile cusco’s speculum 
Pair of gloves
Cotton swabs
Ring forceps
Plastic bucket with plastic bag
Preparation of 5% freshly prepared Acetic acid solution 
5ml glacial acetic acid + 95ml distilled water. 
Preparation of Lugol’s Iodine
6gm potassium iodide + 100ml distilled water + 4gms of Iodine crystals.
Get informed consent about the procedure. Reassure patient that the procedure is 
painless.  Ensure  that  patient  is  fully  relaxed.  Put  the  patient  in  modified  lithotomy 
position.  Introduce and fix unlubricated  bivalved cusco’s speculum under good light 
source.  Down staging  of  cervix  was  done.  Conventional  pap  smear  was  taken  using 
Ayre’s spatula  and endocervical  brush.  Wash away excess  mucus with saline soaked 
swab. Apply 3-5 % acetic acid on the cervix with cotton tipped applicator. Read after 
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1minute. Followed by the application of Lugol’s Iodine.
Aceto whitening +             - VIA Positive
No Aceto whitening - VIA Negative
Mahogany brown or black - VILI Negative
Mustard yellow or saffron coloured - VILI Positive
COLPOSCOPY
Materials
Colposcope 
Bivalved Cusco’s speculum
Cotton tipped swabs
Sterile glove
Normal saline
3% acetic acid
Lugol’s Iodine
Examination table
With  the  patient  in  lithotomy position  cervix  exposed  with  bivalved  Cusco’s 
speculum and colposcope focused on external os at a distance of 20 cms. Cervix and 
vagina  are  gently  cleaned  with  saline  to  remove  mucus  taking  care  not  to  provoke 
bleeding.  Cervix  inspected  for  lesions  like  leukoplakia  ,  viral  condylomata  and 
carcinoma. Then a solution of 3-5 % acetic acid was applied over the cervix gently and 
liberally.  The solution is  mucolytic   changes  the colour  and vascular  pattern after  an 
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interval of 10-30 seconds.  Cervix inspected for colour, surface, columnar epithelium, 
transformation  zone,  squamo  columnar  junction  and  vascular  pattern.  The  vascular 
pattern was again studied using a green filter. Schiller’s Iodine test was done for patient 
with suspicious lesions. 
The  colposcopy  findings  were  reported  based  on  the  terminology  of  4th 
International Congress of cervical pathology and colposcopy in London 1981 and grading 
of atypical colposcopy appearances were done. 
The  special  symbols  for  the  different  colposcopical  patterns  are  used  by  the 
colposcopists to document the colposcopic findings which imitate as closely as possible 
the picture observed in the colposcope.
The two recording systems in Vogue are:
1. Odell diagram - colposcopic lesions may be represented in a circular diagram in 
relation to the OS.
2. Modified Hammond’s graph of cervix.
It  consists  of  3  concentric  circles  with  12  radial  lines  in  clockwise  fashion.  The 
innermost  represents  endocervix,  intermediate  one is  the transformation zone and the 
outermost  is  the  ectocervix.  In  this  graph  the  colposcopic  findings  can  be  recorded 
accordingly. Exact location of the specific lesions can thus be documented.
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Biopsy Cervix
Materials
Sterile glove
Vulsellum
Sim’s Speculum
Light source
Tischler biopsy forceps
Container
10% formalin
The  management  of  abnormal  lesion  was  finally  dependent  upon  the 
histopathological diagnosis. Biopsies were taken from the iodine negative areas or areas 
of atypical colposcopic findings.
Techniques
1.  Punch biopsy 
2. Excision biopsy
3. Wedge biopsy
4. Diathermy loop biopsy
5. Curettage
6. Conization
The  specimens  were  put  in  10%  formalin  and  sent  to  pathology  lab,  where 
paraffin  block  of  tissue  were  made,  sectioned,  stained  with  eosin,  haematoxylin  and 
examined under microscope for evidence of dysplasia or malignancy.
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REVIEW OF LITERATURE
In 1851, Robert Hull marvelled that with the introduction of the vaginal speculum 
a veritable epidemic of uterine disease had appeared.
The existence of a preinvasive stage in the development of cervical cancer has 
been known since Sir John Williams in the Harverian lectures in 1886 presented a use of 
symptomless cancer cervix which is now known as carcinoma in situ.
In  1910  Rubin  described  non-invasive  change  at  the  margins  of  invasive 
carcinoma then came the word carcinoma in situ.
Hinselmann from Germany first published an account of colposcopy in 1925. It 
has become possible to observe cancer at its very earliest stage, by finding changes in the 
cervix which are invisible to the naked eye. He also combined colposcopy with acetic 
acid application.
The  Schillers  test  invented  in  1928  because  of  its  simplicity  has  been  in 
widespread  use  to  distinguish  between  normal  and  abnormal  epithelium  of  portio 
vaginalis of the cervix.
Despite the introduction of colposcope and Schiller’s iodine test, it was not until 
Papanicolaou and Traut described a simple technique of cytology in 1945. The Clinicians 
recognized that at last they have an effective and simple way of detecting premalignant 
lesions of cervix.
The concept of preinvasive disease of cervix was introduced in 1947. Boyes and 
Worth  (1979)  declared  that  introduction  of  cytologic  screening  for  cancer  cervix  in 
developed countries has resulted in considerable reduction in morbidity and mortality 
from the disease, when compared to developing countries like India that don’t have mass 
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cytologic screening. In this context down staging was introduced there by emphasizing 
the value of speculum examination than no screening at all. 
Frisch LE et al (1995) showed that combination of cytologic screening and naked 
– eye inspection of the cervix (NIC) increased the screening yield as compared with a 
Pap  smear  alone  but  with  some  loss  of  positive  predictive  value.  NIC  significantly 
improved the predictive value of negative cytologic screening results (1).
Belinson JL et al (2002) showed that the sensitivity of visual inspection equaled 
or  exceeded  reported  rates  for  conventional  cervical  cytology.  Visual  inspection  and 
colposcopy have similar specificity profiles for CIN II and greater (2).
Mandelblatt JS et al (2002) concluded that well organized screening programs can 
reduce the cervical cancer mortality in less-developed countries at low costs (3).
Tayyeb R et al (2003) concluded that higher sensitivity, accuracy, low cost, easy 
applicability  and immediate  results  make  VIA,  a  useful  screening  test  in  developing 
countries as compared to pap smear (4).
Basu PS et al (2003) by conducting a study in kolkata concluded that VIA and 
VIAM had significantly higher sensitivity than cytology but the specificity of cytology 
was higher than that of VIA and VIAM (5).
Ferreccio  C  et  al  (2003)  showed  that  as  a  single  test,  either  liquid  –  based 
cytology  or  HPV  DNA  testing  was  significantly  more  accurate  than  conventional 
cytology or cervicography. Paired tests incorporating either liquid – based cytology or 
HPV DNA testing were not  substantially more accurate than either of those two test 
strategies  alone.  However  a  possibly  useful  synergy  was  observed  between  the 
conventional smear and cervicography (6).
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Sankaranarayanan R et al (2003) showed that VIA and VILI are suitable atternate 
screening tests to cytology for detecting cervical neoplasia in low resource settings (7).
Bhatla N et al (2004) showed that visual inspection can be performed reliably by 
trained paramedical workers and doctors and is  an effective screening options in low 
resource settings (8).
Denny L et al (2004) concluded that DVI is a low cost, simple primary screening 
test in low resource settings (9).
Sankaranarayanan  R  et  al  (2004)  by  conducting  cross  –  sectional  studies  in 
Mumbai and Kolkata concluded that low level magnification (2-4 x) did not improve the 
test  performance of naked eye visualization of acetic acid impregnated uterine cervix 
(10).
Ghaemmaghami F et al (2004) concluded that the sensitivity and specificity of 
VIA is high and comparable with that of cytology. Hence VIA can be undertaken as a 
feasible  method  of  screening  in  cervical  cancer  in  countries  where  access  to 
cytopathology is    limited (11).
Sankaranarayanan R et  al  (2004) showed that  VILI had a  significantly higher 
sensitivity than VIA in detecting HSIL, but specificity was similar. VILI appears to be a 
more accurate visual test for use in screening and treatment programs in low – resource 
settings (12).
Winkler JL et al (2005) conducted a study in Rural Mexico and showed that i) 
VIAM is more sensitive but less specific than VIA.
   ii) Training of clinical personnel in visual inspection is critical to improve 
the effectiveness of these screening methods (13).
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Derchain SF et  al  (2005) concluded that  VIA and Hybrid capture  II  (HC II) 
contributed to the screening of cervical neoplasia in a group of Brazilian women, but the 
cost effectiveness of conjoint screening modalities is still debatable (14).
De Vuyst H et al (2005) showed that the pap smear had the highest specificity 
(94.6%) and HPV testing the highest sensitivity (94.4%). The visual methods, VIA and 
cervicography, were similar and showed an accuracy in between the former two tests 
(15).
Wu S et al (2005) showed that DNA hybridization assay (HPV) is the best choice 
in primary screening if available. Screening should begin at the age of 20 years (16).
Shastri SS et al (2005) showed that visual tests are promising in low – resource 
settings like India. The use of both VIA and VILI may be considered where good quality 
cytology or HPV testing are not feasible. The sensitivity of cytology and HPV testing 
increased significantly when combined with VIA and VILI (17). 
LAMS (Latin American Screening Study) (2005) compared PAP smear, Aided 
visual inspection, Colposcopy, Cervicography and HPV testing as an optional screening 
tests in Latin America. This study concluded that variation in cervical cancer incidence is 
due to             i) different natural history of the precursor lesions, or ii) Due to different 
levels of exposure to the known risk factors (18).
Valdespino VM et al (2006) showed the papanicolaou test is the best method of 
screening in high resource settings. Visual inspection using cervical dyes is more useful 
method in low resource settings. The challenge for the future is more dependent on local 
finances and screening policies (19).
Elit  L  et  al  (2006)  concluded  that  VIA  has  an  acceptable  test  parameter  for 
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population based – cervical screening in Mongolia compared to cervical cytology (20).
In study by Denny L et al (2006) organized and quality assured cytology – based 
screening  programs  have  substantially  reduced  cervical  cancer  incidence  in  many 
developed countries. However, there are considerable barriers to setting up cytology – 
based screening programs, particularly in developing countries. This has stimulated the 
search for  novel  and alternate  approaches to  cytology for  cervical  cancer  prevention. 
These  approaches  generally  perform as  well  as  cytology,  but  have  lower  specificity 
resulting in higher false positive rates (21).
Sangwa –  Lugoma G et  al  (2006)  showed that  VIA and VILI,  performed by 
nurses and physicians are slightly more sensitive but less specific than Pap cytology. 
Given their  lower cost  and easy deployment,  visual  inspection methods merit  further 
assessment as cervical cancer screening methods for low resource countries (22).
Sodhani  P  et  al  (2006)  concluded  that  VIA,  VIAM  can  be  used  as  a  mass 
screening tool for cervical cancer in resource poor settings due to greater sensitivity (23).
Muwonge R et al (2007), studied the gain in diagnostic performance when two 
visual inspection methods were combined and showed that settings already using VIA 
would advocate combined testing and for settings using VILI to opt for the single test due 
to greater sensitivity of VILI (91.5%) alone and combined testing (92.9%) compared to 
VIA alone (81.3%)  (24).
Arbyn M et al (2008) showed that liquid based cervical cytology is neither more 
sensitive  nor  more  specific  for  detection  of  high  grade  CIN  compared  with  the 
conventional pap test (25).
Dhaubhadel  P  et  al  (2008)  showed  that  VIA as  a  screening  test  for  cervical 
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neoplasia  did  not  miss  any lesion  detected  by pap  smear  and  confirmed by cervical 
biopsy (26).
El – Shalakany AH et al (2008) showed that VILI in feasible, easy to perform 
with superior sensitivity to cervical cytology and VIA in detecting cervical premalignant 
and malignant lesions. VILI can be used as an efficient primary screening tool with a 
satisfactory low biopsy rate in low resource setting (27).
Jun JK et al (2008) showed that women with a normal or benign pap smear had a 
statistically  significantly  lower  risk  of  invasive  cervical  cancer  and  CIS  of  cervix 
compared with those never screened and also that regular screening of cervical cancer 
reduces invasive cervical cancer incidence and CIS of the cervix among Korean women 
(28). 
Davis – Dao CA et al (2008) showed that women with cervicitis were twice as 
likely to have a positive VIA result as women without cervicitis. Presence of cervicitis 
may influence the accuracy of results obtained from colposcopy and VIA (29).
 In study by Arbyn M et al (2008) five screening methods VIA, VILI, VIAM, Pap 
smear, HPV testing with the high risk probe of Hybrid capture -2 assay, were evaluated 
in 11 studies in India and Africa in women aged 25 -64 years. Verification was based on 
colposcopy and colposcopy directed biopsy. Negative colposcopy was accepted as truly 
negative outcome (30). In this study 
VIA showed sensitivity of 79% and 83% specificity of 85% and 84% for CIN 2 + 
and CIN 3+ lesions respectively. 
VILI – 10% more sensitive and equally effective.
VIAM – Similar results as VIA. 
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Pap smear showed lowest sensitivity 57% with high specificity 93% for CIN 2 
lesion.
HC-2 showed sensitivity of 62% and specificity of 94% for CIN II lesion.
In study by Sankaranarayanan R et al (2008) cryotherapy and large loop excision 
of  the  transformation  zone  are  effective  and  safe  treatment  methods  for  cervical 
intraepithelial  neoplasia.  The  clinical  stage  of  cancer  is  the  single  most  important 
prognostic  factor  and  should  be  carefully  evaluated  in  choosing  optimal  treatment 
between surgery and radiotherapy, with or without chemotherapy (31).
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HISTOLOGY OF VAGINA AND CERVIX
The wall of vagina is made up of outer fibrous layer in criss cross special fashion 
and subepithelial connective tissue (elastic) on which the stratified squamous epithelium 
rest.  The epithelium also covers that part of the cervix which projects into the vagina 
known as ectocervix. The squamous epithelium in a sexually matured woman has four 
layer of cells.
Basal
Parabasal
Intermediate
Superficial
EPITHELIUM OF CERVIX
Endocervix – the epithelium is tall columnar type with basal solid nucleus. They 
are thrown into folds and ciliated by but not in the crypts and glands. Beneath this layer 
are  cubical  basal  or  the  reserve  cells  from which  new  surface  cells  are  believed  to 
develop and which undergo squamous metaplasia. 
Ectocervix  –  Epithelium of  portio  vaginalis  is  stratified  squamous  epithelium 
although sub-epithelial papillae are less marked and may be absent. 
Squamo-columnar Junction - The point were the stratified squamous epithelium 
meets the glandular epithelium is termed as the squamo-columnar junction. It’s normally 
situated at the external OS. There is abrupt change in cellular type here.
Transformation Zone – Extends from original squamo columnar junction to active 
squamo columnar junction
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ANATOMIC ZONE
1. Portio Vaginalis which lies beyond the external os lined by stratified squamous 
epithelium.
2. Endocervix bounded by Internal os and External os.
HISTOLOGICAL ZONE
Histological Portio
Cervical stroma without glands lined by squamous epithelium.
Transitional Zone
Originally covered by columnar epithelium gradually transformed to squamous 
epithelium.
Endocervix
Endocervix consists of stroma, glandular epithelium and columnar cells. 
HISTOGENESIS OF TRANSITIONAL ZONE
SITES
  Basal cells of Portio epithelium
 Basal cells of Portio epithelium at the margin of old erosion
 Basal cells of squamous epithelium
 Sub cylindrical cells of endocervix adjacent to histological portio.
26
STAFL MATTINGLY REF AMERICAN JOURNAL OF OBST AND GYN 1974
Pathogenesis of Cancer Cervix
Columnar epithelium
Exposed to Vaginal environment (Low ph of vagina)
Early metaplasia
Physiological Atypical
metaplasia metaplasia
Normal         Abnormal 
Transformation Transformation Zone
Zone
Adequate Inadequate
host response              host response
Well
differentiated                                                No progression           Dysplasia
squamous epithelium                                                       Carcinoma in situ
           Invasive carcinoma
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GOVAN’S CLASSIFICATION OF CERVICAL LESIONS
BENIGN
Squamous hyperplasia
Reactive hyperplasia
Basal cell hyperplasia
Reserve cell proliferation
Metaplaia
1. Complete
2. Incomplete
MALIGNANT
Cervical intra epithelial neoplasia
Mild dysplasia
Moderate dysplasia
Severe dysplasia
Micro invasive carcinoma
Invasive carcinoma
METHODS OF EARLY DIAGNOSIS OF CERVICAL LESIONS
DOWN STAGING IN MASS SCREENING
Naked eye visualization of the cervix without acetic acid nor magnification to 
identify early stages of cancer. Also known as unaided visual inspection.
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In visual Inspection of cervix following are noted :
 Colour, surface, contour of cervix
 Healthy / Unhealthy cervix 
 Cervical polyp
 Ectropion 
 Leukoplakia / condyloma
 Cervical warts
 Nabothian follicle
 Old scars
 Bleeds on touch, stippled cervix
 Hypertrophied elongated irregular edematous cervix
 Hard indurated cervix
 Bleeding cervical erosion
 Suspected growth / ulcer
Rural health workers are taught to conduct speculum examination for all women 
at reproductive age group irrespective of their complaints.
DRAW BACK OF DOWN STAGGING 
Lesions  are  not  detected  early  enough  to  prevent  invasion,  because  a  large 
proportion of the cancers detected are relatively advanced, requiring complex medical 
therapy that is difficult to provide in many settings.
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VISUAL INSPECTION WITH ACETIC ACID (VIA)
VIA was first described by ottaviano and La Torre  in 1981 
Naked eye visualization of uterine cervix without magnification after application 
of diluted 3-5 % acetic acid solution to screen for cervical abnormalities. Also known as 
Cervicoscopy or Direct visual inspection.
MAGNIFIED  VISUAL  INSPECTION  AFTER  APPLICATION  OF   ACETIC 
ACID (VIAM)
Visualization of uterine cervix using low power maginification after application of 
3-5%  acetic  acid  is  known  as  VIAM.  Also  known  as  Gynoscopy  or  Aided  visual 
inspection.
VISUAL INSPECTION WITH LUGOL’S IODINE (VILI)
Visualization of uterine cervix after application of Lugol’s iodine 
MOLECULAR BASIS OF VIA
Acetic  acid  causes  dehydration  of  cells  and  surface  coagulation  of  cellular 
proteins  thereby reducing  the  transparency of  cervical  epithelium.  These  changes  are 
more pronounced in abnormal epithelium due to greater nuclear density and consequent 
higher concentration of proteins enabling much earlier  detection and treatment of pre 
cancerous lesions.
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Acetowhitening can be due to - CIN
Invasive carcinoma 
Immature squamous metaplasia
Healing and regenerating epithelium
Leukoplakia, condyloma
PATHOPHYSIOLOGICAL BASIS OF VILI
Iodine is glycophilic 
VILI
Glycogenated cells Non glycogenated cells
Mature squamous Columnar epithelium                   CIN,
Epithelium       Invasive carcinoma,
      Leukoplakia,
      Condyloma,
Turns mahogany Slightly discoloured             Immature 
Brown / black            Squamous epithelium 
      Turns mustard yellow or
      Saffron coloured
31
ADVANTAGES OF VIA AND VILI
 
1. Simple, easy to learn and perform
2. Inexpensive 
3. Minimal requirement of infrastructure  and equipment 
4. Immediate results 
5. High sensitivity 
6. Preliminary screening of high risk cases for referral
7. Can be competently performed by trained paramedical workers with proper 
training 
8. Potential for integration into PHC services 
9. Requires one visit 
10. Decreased loss to follow up.
DISADVANTAGES OF VIA AND VILI
1. Moderate specificity – resulting in higher referral and potential over treatment in a 
single visit approach.
2. Dependence on person doing the evaluation (subjective)
3. Need for standard training mehods and quality assurance.
4. Lower accuracy in postmenopausal women, because transformation zone recedes 
into the cervical canal at menopause.
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IARC CRITERIA FOR INTERPRETATION OF VIA AND VILI
VIA Positive
 Well  defined,  sharp,  distinct,  dense  acetowhite  areas  with  or  without 
raised  margins,  abutting  the  squamo-columnar  junction  in  the 
transformation zone
 Strikingly dense acetowhite area in the columnar epithelium
 Condyloma  and  leukoplakia  occurring  closer  to  the  squamo-columnar 
junction turning intensely white after application of acetic acid
VIA Negative
 No acetowhite lesions on the cervix
 Polyps protruding from the cervix with bluish-white acetowhite   
     areas
 Nabothian cysts appearing as button-like areas / whitish acne, or pimples
 Faint line-like or ill-defined acetowhitening at squamocolumnar junction
 Shiny, pinkish-white, cloudy-white, faint patchy, or doubtful lesions with 
ill-defined, indefinite margins, blending with the rest of  the cervix
 Angular, irregular, digitating, acetowhite lesions resembling geographical 
regions far away from the transformation zone (satellite lesions)
 Ill  – defined,  patchy,  pale acetowhite  areas  in the inflamed, unhealthy, 
ulcerated cervix with bleeding and mucopurulent discharge
 Streak –like acetowhitening in the columnar epithelium
 Red  spots  on  cervix  against  pinkish  white  background  after  applying 
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acetic acid
 Dot-like areas in the endocervix,  which are due to grape-like columnar 
epithelium staining with acetic acid
VILI Positive
 Dense, thick, bright, mustard-yellow or saffron yellow iodine non- uptake 
areas abutting the squamo-columnar junction in the transformation zone
VILI Negative
 Normal  cervix  where  squamous  epithelium  turns  mahogany  brown  or 
black  and the  columnar  epithelium does  not  change colour;  no yellow 
areas seen; 
 In ectropion, when an extensive area of columnar epithelium with regular 
margins on the ectocervix remains without colour change
 Patchy, indistinct, ill-defined, colourless or partially brown areas are seen 
in the cervix
 Non-  or  partial-iodine  uptake,  pale  areas  corresponding  to  pre-existing 
nabothian follicles and /or polyps are seen
 Stippling or leopard skin appearance associated with T. vaginalis infection
 When  pepper-like  non-iodine  uptake  areas  seen  in  the  squamous 
epithelium far away from the squamo-columnar junction
 When  satellite,  thin,  yellow,  non-iodine  uptake  areas  with  angular,  or 
digitating margins resembling geographical areas are seen far away from 
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the squamo-columnar junction.
OTHER VISUAL INSPECTION APPROACHES
CERVICOGRAPHY
Cervicography entails photographing the cervix after application of   3-5% diluted 
acetic acid, with a uniquely designed camera. The photographs called Cervigrams, are 
viewed as projected slides by colposcopists  trained in their  interpretation.  It  is useful 
when a colposcopist is not available for spot evaluation.
SPECULOSCOPY
Speculoscopy is  a  technique  where  acetic  acid  is  applied  to  the  cervix,  but  a 
chemical or chemiluminescent light-source and magnifying lens are used to visualize the 
acetowhite lesions of the cervix.
35
PAP SMEAR (SURFACE BIOPSY)
Dr. George N. Papanicolaou in 1928 reported malignant cells from the cervix in 
vaginal smear taken from vagina using pipette (“Exfoliative cervical cytology”). 
Dr.  Herbert  Trait  (Gynaecologist)  helped  Papanicolaou  by  providing  clinical 
samples.
Dr. J. Ernest Ayre (Canadian Gynaecologist) took smear from the cervix using 
wooden spatula. 
Pap is the screening test that detects 98% of cancer cervix and 70% endometrial 
cancer (shaw text book).
False positive result is reported in the presence of infection.
Types of Pap Smear
1. Conventional smear
2. Liquid based preparation 
- Thin prep
- Sure path
3. Auto pap screening system
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REPORTING SYSTEM
Papanicolaou Class System (1943)
I - Normal cells
II - Slightly abnormal, suggestive of inflammatory change, repeat smear  
            after treating the infection 
III - A more serious type of abnormality, usually indicative of the need  
            for biopsy
IV - Distinctly abnormal, possibly malignant and definitely requiring 
             biopsy 
V - Malignant cells seen
WHO CIN BETHESEDA (III) 2001
Negative Negative With in normal limits
Atypical squamous cells Inflammatory Inflammatory 
- infection
- reactive / reparative 
changes
ASCUS (Atypical squamous cell of 
undetermined significance)
Mild dysplasia CIN I Low grade squamous intraepithelial 
lesion (LSIL)
Moderate dysplasia 
Severe dysplasia 
Carcinoma in situ
CIN II
CIN III
High grade squamous intraepithelial 
lesion (HSIL)
Invasive Carcinoma Invasive Carcinoma Invasive Carcinoma
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I - Normal pap smear
- Basal layer cells (small rounded basophilic with large nuclei)
- Middle layer cells (squamous cells, transparent, basophilic with vesicular 
nuclei)
- Superficial layer cells (acidophilic with pyknotic nuclei)
Nuclear cytoplasmic ratio is increased in malignant cells.
II – Cervical Intraepithelial Neoplasia
CIN I
Mild  dysplasia,  undifferentiated  cells  involving  the  lower  1/3 of  epithelium. 
Smears have predominantly superficial and intermediate cells with few dysplastic cells.
CIN II
Moderate dysplasia, undifferentiated cells occupying the lower and middle third 
layer and smear have cells intermediate between CIN I and CIN III.
CIN III
Severe dysplasia, undifferentiated cells almost reaches the surface except a few 
mature cells in the superficial layer. Smears have predominantly dysplatic cells with very 
few superficial cells.
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CIS
The  entire  thickness  is  replaced  by  undifferentiated  cells  with  no  mature 
superficial cells. Basement membrane is intact without any breach.
IN SMEAR IT HAS TWO CLASSICAL TYPE
1. Undifferentiated type
Have  syncytial  sheets  with  poorly  defined  outline.  Indistinct  or  absent 
intercellular  border.  Cyanophilic  cytoplasm  with  gauge  like  texture.  Closely  packed 
nuclei with no cytoplasm. Nuclear chromatin is irregular in distribution and increased in 
amount finely stippled and condensed into coarse aggregates.
2. Malignant parabasal cells
Discrete round or oval have a disproportionately large hyperchromatic nuclei with 
coarse condensed chromatin. Degenerative changes seen.
III – Invasive Squamous Cell Carcinoma
1. Well differentiated
Pleomorphic tad pole with bulbous head and long tail and contain keratin.
2. Moderately differentiated
Recognizable  squamous  cells  with  intercellular  bridges  but  without  keratin. 
Pleomorphic cells with considerable variation in size and shape.
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3. Undifferentiated
Small and immature nuclei, large oval or spindle shaped and in syncitial sheets 
smaller than in carcinoma in situ.
Adenocarcinoma
The cytoplasm tend to be abundant and textured frequently blue lavender tinge 
more  granular  and  vacuolated.  Nuclei  and  nucleoli  are  always  present  and  may  be 
multiple. The non secreting cells show increased nuclear cytoplasmic ratio.
FEATURES VARIATIONS WITH INCREASING SEVERITY OF DYPLASIA
Decrease Increase Varies
Cellular cohesion Mitosis Nuclear hypertrophy
Amount of cytoplasm Nuclear/ cytoplasmic ratio Antisokaryosis
Multinucleation Anisochromatosis Hyperchromatism 
Degree of maturation Nuclear 
membrane irregularities
Nucleoli 
ICMR New Delhi (women more than 30 years) reported 5 to 15 smears to be 
abnormal per 1000 women. 
AIMS reported 16 smears to the abnormal per 1000 women
Reference. Shaw’s text book of gynaecology
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SCREENING GUIDELINES
Guidelines American Cancer Society ACOG
Initial  screening Age 21 or 3 years after vaginal sex Age 21 or 3 years after vaginal 
sex
Interval -Every year for  conventional pap
-Every 2 years for liquid based pap
-Every 2-3 years after age 30 with 3    
  consecutives normal
-Every year for either   
 liquid based pap or  
 conventional pap 
-Every 2-3 years after age  
 30 with 3 consecutives  
 normal
Discontinue Age 70 if 3 consecutives normal in 10 
years
No upper limit of age
IARC SCREENING GUIDELINES
 An organized  screening  programme   should  cover  women  aged  25-65 
years.
 IARC advises  that  annual  screening  smears  are  unnecessary even with 
conventional cytology.
 Screening of women less than 25 years of age offers minimal benefit.
 For  woman  25  –  49  years  of  age  three  yearly  pap  smears  are 
recommended, five yearly where resources are limited.
 Five yearly smears from 50-65 years of age are recommended.
 Screening can cease after 65 years of age provided there are no suspicious 
results in the previous two tests. 
PROGRESSION OF CIN TO CIS AND INVASIVE CARCINOMA
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ASCUS – 10 – 20% risk of CIN I 
3 – 5% risk of CIN II and III
LSIL (CIN I) 
- Undergoes spontaneous regression in 60 – 85% of  cases  within 2 
years of follow up with cytology and  colposcopy.
- 25% risk of CIN II and CIN III with in two years.
- if lesions progresses during follow up or persist at two years treat with 
ablation therapy.
HSIL (CIN II and III)      
- Do colposcopic directed biopsy. If biopsy positive for HSIL, do Large
  Loop Electrosurgical Excision Procedure (LEEP).
- CIN II and III progresses to CIS in 20% of the  cases, invasive
   carcinoma in 5% of the cases.
CIS – Progresses to invasive carcinoma in 5% of the cases 
Reference. Novak’s Text book of Gynaecology
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COLPOSCOPY
In  1925,  Hinselman  in  Germany devised  the  first  colposcope  from which  the 
modern  day  instruments  have  evolved.  These  are  binocular  instruments  giving  a 
stereoscopic magnification of 10-20 times.
Indication for Colposcopy
1. Abnormal pap smear cytology 
2. To locate abnormal areas
3. To obtain directed biopsy 
4. Conservative therapy under colposcopic guidance
5. Follow up of cases treated conservatively
COLPOSCOPIC FINDINGS 
I  Normal Colposcopic findings:
1. Normal Squamous Epithelium
- Smooth, pink, uniform, featureless epithelium
- Stains Positively for glycogen
2. Columnar Epithelium
-  Appear  as  villi  with  capillary  loops  and  covered  by  mucus.  After 
application of acetic acid it has a typical grape like appearance.
43
3. Normal Trasformation Zone 
Components  of  transformation  Zone  may  be  islands  of  columnar  epithelium 
surrounded by metaplastic squamous epithelium, gland openings, and nabothian cysts.
Stromal vessel have a characteristic tree like branching pattern. 
II. ABNORMAL COLPOSCOPIC FINDINGS
A. Atypical Transformation Zone
1. Leucoplakia
White  epithelium that  is  present  before  the  application  of  acetic  acid. 
Caused by a layer of keratin on the surface of the epithelium.
2. Acetowhite Epithelium
Seen after application of acetic acid. Metaplastic and dysplastic epithelium 
appear as white or grayish white due to increased cellular nuclear density. Normal cells 
appear pink.
3. Iodine Negative Epithelium
Doesn’t stain with Lugol’s or Schiller’s Iodine. Normal native squamous 
epithelium stains brown.
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4. Punctation
Punctation may be seen within the acetowhite areas. These are the terminal 
ends of   dilated capillaries.
5. Mosaic
Terminal capillaries may surround circular or polygonal area of acetowhite 
epithelium to give the appearance of mosaic.
6. Atypical Vessels
There  is  gross  variation  in  caliber  and  course  with  bizarre  irregular 
branching, sometimes appearing as commas, corkscrews or spaghetti like forms.
B. SUSPECT INVASIVE CARCINOMA
1. Irregular surface contour with loss of surface epithelium.
2. colour  tone  changes  to  yellow orange  rather  than  the  expected  pink  of  intact 
squamous epithelium and red of endocervical epithelium.
3. Abnormal blood vessels 
 Abnormal looped vessels are the most common colposcopic findings and 
arise from the punctated and mosaic vessels present in CIN.
 Abnormal  branching  vessels  tend  to  form obtuse  or  right  angles  with 
caliber sometimes enlarging after branching . 
 Abnormal  reticular  vessels  represent  the  terminal  capillaries  of  the 
cervical epithelium.
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III. UNSATISFACTORY COLPOSCOPIC FINDINGS
If the entire squamocolumnar junction is not visible it’s judged unsatisfactory.
IV. MISCELLANEOUS COLPOSCOPIC FINDINGS
Seen in inflammations, atrophic changes, true erosion, condyloma and papilloma. 
They are not related to cervical neoplasia and are present both in the transformation zone 
and in original squamous epithelium.
COLPOSCOPIC GRADING
BASED ON COPPLESON AND REID
1. Grade I (insignificant, not suspicious)
Flat white epithelium, fine caliber and regular vessels with small inter capillary 
distance – Normal epithelium to minor dysplasia.
2. Grade II (significant, suspicious)
Flat, white epithelium, vessels with dilated caliber and regular shape absence of 
atypical vessels and increased inter capillary distance – moderate dysplasia to carcinoma 
in situ.
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3. Grade III ( Highly significant, highly suspicious)
Markedly white epithelium irregularly shaped and dilated vessels with variable 
intercapillary  distance  and  irregular  surface  –  carcinoma  in  situ  to  early  invasive 
carcinoma.
Reid Scalzi Score
Based on four colposcopic signs 
- Margin 
- Colour
- Vessels
- Iodine test
Score 0-2 – CIN I
3-5 – CIN I to II
6-8 – CIN II to III
COLPOMICROSCOPY
Magnification is  100 – 300 times.  Looks at  the structure at  the cellular  level. 
Interpretation is not very easy hence its lack of popularity.
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BIOPSY CERVIX
Indication for Biopsy
1. All cases of leukoplakia even in the presence of negative smear 
2. Lesions of squamous epithelium which whiten after acetic acid application.
3. All other abnormal lesions including those which are difficult to interpret at 
colposcopy.
In the presence of obvious cervical lesions punch biopsy or wedge biopsy may be 
taken. 
Colposcopic  directed  biopsy is  more  specific  and  avoids  lot  of  false  negative 
biopsies.
Indications for Cone Biopsy 
1. When the area of abnormality is large.
2. When the squamo columnar junction is not visible completely on colposcopy.
3. When the inner margin of the lesion has receded into the cervical canal.
4. When there is discrepancy between colposcopy, cytology and biopsy.
5. Endocervical curettings positive for CIN II or III.
6. Colposcopically directed biopsy positive for micro invasion.
7. Colposcopy is unable to rule out invasive cancer.
Complications of Cone Biopsy
Bleeding, infection, cervical stenosis and incompetance.
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NEWER TECHNIQUE 
HPV DETECTION
By  
1. Cytology (pap smear)
2. Histology 
3. Electron microscopy
4. Immuno histochemistry (Identification of group specific antigen)
5. Molecular test
a. Insitu hybridization 
b. Dot blot test
c. By amplification of viral DNA
I. Target amplification (PCR)
II. Signal amplification (hybrid capture II)
6. Serology (Detection of viral capsid proteins) 
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EPIDEMIOLOGY, AETIOLOGY, RISK FACTOR OF CANCER CERVIX
1. Coitus before 18 years of age.
2. Multiple sexual partners.
3. Delivery of first baby before 20 years.
4. Multi parity with poor birth spacing between pregnancies.
5. Poor personal hygiene.
6. Poor socio economic status.
7. Smoking, alcohol, drug abuse.
8. History of sexually transmitted diseases, TB, HIV, HPV, HSV2, condyloma.
9. Immuno suppressed.
10. OC pills intake.
11. History of prior genital tract dysplasia.
12. Women who do not come for regular health check up / lack of prior pap smear 
screening.
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The two Canadian task forces considered that the adult female population can be 
classified into two groups.
1. Group that is not at risk and should not be included in the screening  
    program for cancer cervix comprising.
- Women who had never been sexually active.
- Women over 60 who had been screened in the past and had no atypia in 
their smears.
- Women  who  had  a  hysterectomy  for  benign  disease  with  complete 
removal of cervical epithelium.
2. The group at risk for cancer cervix (ie.) women over 18 years and  
     under 60 years who are or have been sexually active.
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RESULTS
The study was conducted  on  500 women attending  the  Gynaecology OPD of 
GOVERNMENT RSRM LYING IN HOSPITAL CHENNAI – 13 for a period of two 
years  (2006-08).  A  detailed  history  was  taken.  General  examination  and  vital  signs 
assessment  was  done.  All  500  women  were  subjected  to  down  staging,  pap  smear, 
VIA,VILI,  and  colposcopic  examination.  Colposcopy  directed  biopsy  was  taken  in 
women with abnormal colposcopic findings and the results were tabulated as follows.
AGE DISTRIBUTION
TABLE – 1
Age group No. of Women Percentage
20 – 30 years
31 – 40 years
41 – 50 years
51 – 60 years
241
185
  58
  16
48.2%
37%
11.6%
3.2%
85.2% of the women in the study group were aged between 20 – 40 years.
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PARITY DISTRIBUTION
TABLE- 2
Parity No. of Women Percentage 
1
2
3
4
5
6
8
  40
290
117
  33
  11
    8
    1
8%
58%
23.4%
6.6%
2.2%
1.6%
0.2%
88% of the women in the study group belong to para 2 – 4.
Though the incidence of unhealthy cervix was similar to healthy cervix in para 2 – 
4,  number  of  women  with  unhealthy  cervix  was  considerably  lower  in  para  1  and 
considerably higher in para 4.
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MARRIED YEARS DURATION
TABLE-3
Married Years Duration No. of Women Percentage
03 – 10 
11 – 20
21 – 30
31 – 40
> 40
168
229
 84
 16
 03
33.6%
45.8%
16.8%
3.2%
0.6%
Mean married years duration in the study group was 15.28 years.
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COMPLAINTS 
TABLE-4
Complaints No. of Women Percentage
White Discharge
Lower Abdominal Pain
Low Backache
Intermenstrual Bleed
Post Coital Bleed
323
105
  57
  07
  08
64.6%
21%
11.4%
1.4%
1.6%
Most of the women presented with complaints of persistent white discharge per 
vaginum.
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DOWN STAGING OF CERVIX
TABLE-5
Down Staging of Cervix No. of  women Percentage
Healthy Cervix 263 52.6%
Unhealthy Cervix
1. Erosion
2. Hypertrophy
3. Ectropion
4. Congestion 
5. Old Cervical Tear
6. Polyp
7. Ulcer
133
  37
  23
  21
  11
    8
    4
26.6%
7.4%
4.6%
4.2%
2.2%
1.6%
0.8%
In speculum examination 263 women had healthy cervix and 237 women had 
unhealthy cervix of which erosion cervix is the commonest.
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RESULTS OF VIA
TABLE-6
VIA Biopsy Positive for 
CIN/CA Cervix
Biopsy Negative for 
CIN/CA Cervix
Total
Positive 64 70 134
Negative 23 343 366
Total 87 413 500
VIA  was  positive  in  134  women,  negative  in  366  women.  VIA  was 
positive in 64 women with biopsy report positive for CIN/CA Cervix and 70 women with 
biopsy report negative for CIN/CA Cervix. VIA was negative in 23 women with biopsy 
report positive for CIN/CA Cervix and 343 women with biopsy report negative for CIN/
CA Cervix.
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VIA vs BIOPSY
TABLE-7
Biopsy VIA Positive VIA Negative
CIN I
CIN II
CIN III
Squamous Cell Carcinoma
34
16
07
07
18
05
-
-
Total 64 23
VIA was  positive  in  64  women with  biopsy report  positive  for  CIN and CA 
cervix. Of which VIA was positive in 34 women with CIN I, 16 women with CIN II, 
7 women with CIN III, and 7 women with squamous cell carcinoma.
VIA was negative in  23 women with biopsy report  positive  for  CIN and CA 
cervix. Of which VIA was negative in 18 women with CIN I and 5 women with CIN II. 
VIA detected all cases of CIN III and squamous cell carcinoma.
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RESULTS OF VILI
TABLE-8
VILI Biopsy Positive for 
CIN/CA Cervix 
Biopsy Negative for 
CIN/CA Cervix 
Total
Positive 61 66 127
Negative 26 347 373
Total 87 413 500
VILI was positive in 127 women and negative in 373 women. VILI was positive 
in 61 women with biopsy report positive for CIN/CA cervix and 66 women with biopsy 
report negative for CIN/CA cervix. VILI was negative in 26 women with biopsy report 
positive for CIN/CA cervix and 347 women with biopsy report  negative for CIN/CA 
cervix.
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VILI vs BIOPSY
TABLE-9
Biopsy VILI Positive VILI Negative
CIN I
CIN II
CIN III
Squamous Cell Carcinoma
33
16
06
06
19
05
01
01
Total 61 26
VILI was positive in  61 women with biopsy report  positive for  CIN and CA 
cervix. Of which VILI was positive in 33 women with CIN I, 16 women with CIN II, 6 
women with CIN III, and 6 women with squamous cell carcinoma.
VILI was negative in 26 women with biopsy report  positive for CIN and CA 
cervix. Of which VILI was negative in 19 women with CIN I, 5 women with CIN II, 1 
women with CIN III and 1 women with squamous cell carcinoma.
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PARITY vs VIA and VILI
TABLE-10
Parity No. of Women VIA Positive VILI Positive
1
2
3
4
> 5
  40
290
117
  33
  20
02
54
42
23
13
03
51
42
18
13
Total 500 134 127
As the parity increases VIA and VILI positivity increases.
MARRIED YEARS DURATION VS VIA AND VILI
TABLE-11
Married Years Duration No. of Women VIA Positive VILI Positive
03-10
11-20
21-30
31-40
> 40
168
229
 84
 16
 03
13
59
48
11
03
14
64
38
08
03
Total 500 134 127
As the married years duration increases VIA and VILI positivity increases
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PAP SMEAR GRADING
TABLE-12
Grade No. of Women
I (Normal)
II (Inflammatory)
III (CIN-I)
IV (CIN-II & III)
V (SCC)
222
200
  56
  22
 ---
Total 500
Pap  smear  study  revealed  222  women  with  normal  cytology  (Grade  I),  200 
women had inflammatory smear (Grade II), CIN I (Grade III) in 56 women, CIN II and 
III (Grade IV) in 22 women.
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COLPOSCOPIC FINDINGS
TABLE-13
Grade No. of Women
Normal
I
II
III
356
  88
  42
  14
Total 500
 A detailed colposcopic examination was done in 500 women. 356 women had 
normal colposcopic findings. 144 women had abnormal colposcopic findings, of this 88 
women had grade I lesions, 42 women had grade II lesions, 14 women had grade III 
lesions.
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COLPOSCOPY DIRECTED BIOPSY CERVIX
TABLE-14
Biopsy Findings No. of Women
Biopsy not taken
Normal
Chronic cervicitis
CIN I
CIN II
CIN III
Squamous cell carcinoma
356
  29
  28
  52
  21
  07 
  07
Total 500
Colposcopy directed biopsy was not taken in 356 women with normal colposcopic 
findings.  Colposcopy  directed  biopsy  was  taken  in  144  women  with  abnormal 
colposcopic  findings.  Of  these  histology  was  normal  in  29  women,  28  women  had 
chronic cervicitis,  CIN I was seen in  52 women,  CIN II  in 21 women, CIN III  in 7 
women and squamous cell carcinoma in 7 women. 
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DISCUSSION
The concept of screening has been defined as the search for unrecognized disease 
or defect by means of rapidly applied tests, examination or other procedures in apparently 
healthy individual. Today screening is considered a preventive care function and a logical 
extension of health care. The basic purpose of screening is to sort out from a large group 
of apparently healthy persons those likely to have the diseases and to bring those who are 
apparently abnormal under medical supervision and treatment.
The case detection, control of disease, research and education are the 4 main uses 
of the screening programme. A mass screening when backed up by suitable treatment 
reduces the duration of illness or alters its final outcome.
Selective screening is more productive, for example cancer cervix tends to occur 
relatively less often in the upper socio economic groups. Therefore screening of cancer 
cervix  in  the  lower  socio  economic  groups  will  increase  the  yield  of  more  cases. 
Acceptability and repeatability depending on the technique, observer variation, subject 
variation and errors are to be taken into account in mass campaigns.
AGE AND PARITY
      MEAN AGE OF WOMEN
Our study  - 33.11 years  
Kasper et al.,   - 32.5 years 
Kenneth Francus  - 33.25 years
Dunn  - 27 years
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                                  TABLE-15                       
 
Mean age of the women in biopsy negative group was 31.6 % 
Mean age of the women in biopsy positive group was 40.2 %
P value < 0.001 hence highly statistically significant.
Based on a study in Eden Hospital Medical College, Calcutta by Roy Chowdry, 
1975, cancer cervix is common in lower age group. In India 40% were between 36- 40 
years and 50% married below 16 years with early onset of sexual activity. In our study 
40% women were between 31 - 40 years.
He also points out that cancer cervix is common in multi para (95%). In our study 
out  of 87 women diagnosed as  dysplasia  none were para 1,  22 women were para 2, 
65 women were more than para 3.
SOCIO ECONOMIC STATUS
According to two cases – control studies carried out in Columbia and Spain it was 
found that cancer cervix is more common in women of low socioeconomic status than 
women  of  high  socio  economic  status.  The  reasons  being  sexual  behavior  of  men 
particularly contact  with sex workers and HPV infection.  The women of  high socio-
economic status have other risk factors like smoking and oral contraceptive pill use.
In our study all women belong to socio economic status IV and V.
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MARRIED YEARS DURATION
TABLE-16
Biopsy No. of Women Mean Married Years duration
Negative for CIN/CA cervix 413 13.59
Positive  for CIN/CA cervix 87 23.31
Mean married years duration in biopsy negative individual was 13.59 years 
Mean married years duration in  biopsy positive individual was 23.31 years
P value < 0.001 hence highly statistically significant
VIA vs BIOPSY
TABLE-17
VIA Biopsy Positive for 
CIN/CA Cervix
Biopsy Negative for 
CIN/CA Cervix   
Total
Positive 64   70 134
Negative 23 343 366
Total 87 413 500
Sensitivity = 73.56%
Specificity = 83.05%
Positive Predictive Value (PPV) = 47.76%
Negative Predictive Value (NPV) = 93.72%
Diagnostic Accuracy = 81.4%
% of False Positive = 16.94%
% of False Negative = 26.43% 
SENSITIVITY, SPECIFICITY, PPV, NPV OF VIA BY VARIOUS STUDIES
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TABLE-18
Study Year Sensitivity Specificity PPV NPV
El-Shalakany AH et al.,
Arbyn M et al.,
Muwonge R et al.,
Elit L et al.,
De Vuyst H et al.,
Sankaranarayanan R et al., 
Our Study
2008
2008
2007
2006
2005
2004
2008
90.9%
83%
81.3%
82.9%
73.3%
76.8%
73.56%
94.6%
85%
87.3%
88.6%
80%
85.5%
83.05%
43.5%
47.76%
99.6%
93.72%
Our study showed sensitivity of about 73.56% which is comparable with that of 
De Vuyst  H et  al.,  2005 and Sankaranarayanan  R et  al.,  2004 whose  study showed 
sensitivity of about 73.3% and 76.8% respectively. The sensitivity shown by Elit L et al., 
2006, Muwonge R et al., 2007, Arbyn M et al., 2008, El-Shalakany AH et al., 2008, is 
some what higher when compared to our study.
Our study showed specificity of about 83.05% which is comparable with that of  
De Vuyst H et al., 2005, Sankaranarayanan R et al., 2004 and Arbyn M et al., 
2008,  whose  study showed  specificity  of  about  80%,  85.5%,  85% respectively.  The 
specificity shown by Elit L et al., 2006, Muwonge R et al., 2007, is some what higher 
when compared to our study.
VILI vs BIOPSY
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TABLE-19
VILI Biopsy Positive for 
CIN/CA Cervix
Biopsy Negative 
for CIN/CA Cervix 
Total
Positive 61   66 127
Negative 26 347 373
Total 87 413 500
Sensitivity = 70.11%
Specificity = 84.02%
Positive Predictive Value (PPV) = 48.03%
Negative Predictive Value (NPV) = 93.03%
Diagnostic Accuracy = 81.6%
% of False Positive = 15.98%
% of False Negative = 29.88% 
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SENSITIVITY, SPECIFICITY, PPV, NPV OF VILI BY VARIOUS STUDIES
TABLE-20
Study Year Sensitivity Specificity PPV NPV
El-Shalakany AH et al.,
Arbyn M et al.,
Muwonge R et al.,
Sangwa Lugoma G et al.,
Shastri SS et al.,
Sankaranarayanan R et al., 
Our Study
2008
2008
2007
2006
2005
2003
2008
97.7%
93%
91.5%
68.3%
75%
87.2%
70.11%
94.6%
85%
86.9%
76.2%
84%
84.7%
84.02%
46.2%
48.03%
99.9%
93.03%
Our study showed sensitivity of about 70.11% which is comparable with that of 
Sangwa Lugoma G et al., 2006 Shastri SS et al., 2005 whose study showed sensitivity of 
about 68.3% and 75% respectively. The sensitivity shown by Sankaranarayanan R et al., 
2003, Muwonge R et al., 2007, Arbyn M et al., 2008, El-Shalakany AH et al., 2008, is 
some what higher when compared to our study.
Our study showed specificity of about 84.02% which is comparable with that of 
Sankaranarayanan R et al., 2004, Shastri SS et al., 2005, Muwonge R et al., 2007, Arbyn 
M et  al.,  2008,  whose  study showed  specificity  of  about  84.7%,  84%,  86.9%,  85% 
respectively. The specificity shown by El-Shalakany AH et al., 2008 is some what higher 
when compared to our study.
PAP SMEAR vs BIOPSY
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TABLE-21
 Pap Smear Biopsy Positive for 
CIN/CA Cervix
Biopsy Negative for CIN/
CA Cervix 
Total
Positive 69     9 78
Negative 18 404 422
Total 87 413 500
Sensitivity = 79.31%
Specificity = 97.82%
Positive Predictive Value (PPV) = 88.46%
Negative Predictive Value (NPV) = 95.73%
Diagnostic Accuracy = 94.6%
% of False Positive = 2.17%
% of False Negative = 20.6%
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SENSITIVITY,  SPECIFICITY,  PPV,  NPV  OF  PAP  SMEAR  BY  VARIOUS 
STUDIES
TABLE-22
Study Year Sensitivity Specificity PPV NPV
El-Shalakany AH et al.,
Arbyn M et al.,
Sodhani P et al.,
Elit L et al
Sangwa Lugoma G et al.,
Shastri SS et al.,
Sankaranarayanan R et al., 
Our Study
2008
2008
2006
2006
2006
2005
2003
2008
22.7%
57%
91.4%
88.6%
31-72%
57%
81.9%
79.31%
97.6%
98.6%
86.6%
98.5%
94-99%
98.6%
87.8%
97.82%
41.7%
51.7%
88.46%
96.6%
99.8%
95.73%
Our study showed sensitivity of about 79.31% which is comparable with that of 
Sankaranarayanan R et al., 2003, whose study showed sensitivity of about 81.9%. 
Our study showed specificity of about 97.82% which is comparable with that of  , 
Shastri SS et al., 2005, Sangwa Lugoma G et al., 2006, Elit L et al., 2006, Arbyn M et al., 
2008, El-Shalakany AH et al., 2008  whose study showed specificity of about 98.6%, 
94-99%, 98.5%, 98.6%, and 97.6% respectively. 
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COMPARING  THE  SENSITIVITY  AND  SPECIFICITY  OF  VIA,  VILI,  PAP 
SMEAR IN THE DETECTION OF PREINVASIVE LESIONS AND INVASIVE 
CARCINOMA OF CERVIX
TABLE-23
Screening Method Sensitivity Specificity Percentage of 
False Positive
VIA
VILI
Pap Smear
73.56%
70.11%
79.31%
83.05%
84.02%
97.82%
16.94%
15.98%
2.17%
In our study, sensitivity of VIA (73.56%) and VILI (70.11%) is almost similar to 
pap  smear  (79.31%)  but  the  specificity  of  pap  smear  (97.82%)  is  some  what  high 
compared to VIA (83.05%) and VILI (84.02%).
Hence  VIA  and  VILI  has  similar  sensitivity  to  pap  smear  but  with  lower 
specificity in the detection of pre invasive lesions of cervix. This is associated with a high 
number of false positive rates. The observed high number of false positive results of VIA 
and VILI may lead to high rates of referral and may increase the rates of treatment which 
may translate to higher costs. On the other hand high detection rate of VIA and VILI for 
high grade pre-malignant lesions may prevent malignancies at a low cost.  
73
CORRELATION  OF  VIA,  VILI,  PAP  SMEAR,  AND  COLPOSCOPY  WITH 
COLPOSCOPY  DIRECTED  BIOPSY  IN  THE  DETECTION  OF  CIN  AND 
INVASIVE CARCINOMA IN 144 CASES
TABLE-24
Type of 
Lesion
Colposcopy  Colposcopy 
Directed Biopsy
VIA VILI Pap Smear
CIN 137 80 57 55 62
Invasive
Carcinoma
    7   7   7   6   7
Total 144 87 64 61 69
Colposcopic  findings  were abnormal  in  144 women.  Colposcopic examination 
detected  137  women  with  CIN  and  7  women  with  invasive  carcinoma.  Colposcopy 
directed biopsy was taken in 144 women. Biopsy confirmed 80 women with CIN and 7 
women with invasive carcinoma. Of this VIA was positive in 57 women with CIN and 7 
women with invasive carcinoma, VILI was positive in 55 women with CIN and 6 women 
with  invasive  carcinoma and pap  smear  was  positive  in  62  women with  CIN and 7 
women with invasive carcinoma.
VIA failed to detect 5 women with CIN, VILI failed to detect 7 women with CIN 
when compared to pap smear. VIA detected all women with invasive carcinoma where as 
VILI failed to detect one women with invasive carcinoma when compared to pap smear.
SUMMARY
The study was  conducted  on 500 patients  attending  the  gynaecology OPD of 
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GOVERNMENT RSRM LYING IN HOSPITAL – CHENNAI during a period of two 
year  (2006-08).  All  women  were  married  from  reproductive  age  group  to  post 
menopausal age group, maximum between 20 – 40 years. Parity varies from primipara to 
multipara. All women belong to low socio economic class. Most of the women presented 
with more than one complaint, maximum being white discharge. Mean married year’s 
duration was 15 years. Most of them were married at the age of 16 – 18 years with early 
onset of sexual activity.  
             All these women were subjected to down staging, Pap smear, VIA, VILI and 
colposcopic examination. Colposcopic examination was abnormal in 144 women. They 
were subjected to colposcopy directed biopsy. Biopsy detected 80 women with CIN and 7 
women with  invasive  carcinoma.  Of  this  VIA,  VILI,  Pap smear  detected  57,  55,  62 
women with CIN and 7, 6, 7 women with invasive carcinoma respectively. 
             The sensitivity, specificity of VIA, VILI, Pap smear are as follows 
Screening Method Sensitivity Specificity
VIA
VILI
Pap Smear
73.56%
70.11%
79.31%
83.05%
84.02%
97.82%
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CONCLUSION
Visual inspection of the cervix after application of acetic acid and Lugol’s Iodine 
can be used as one of the low cost screening tool in the detection of pre invasive lesions 
of cervix. VIA and VILI has a similar sensitivity to cervical cytology but with lower 
specificity. This is associated with high number of false positive rate leading to high rates 
of referral. On the other hand high detection rate of VIA and VILI for high grade pre 
malignant lesions may prevent malignancy at a low cost. Hence VIA, VILI can be under 
taken as a feasible method of screening in cervical cancer in countries where access to 
cytopathology is limited. 
The sensitivity of cytology increased significantly when combined with VIA and 
VILI. 
Visual inspection can be performed easily by trained paramedical workers in rural 
areas for early referral to higher centers. This may ultimately bring down the severity of 
CIN and Cancer cervix in the long run.
The  higher  sensitivity,  accuracy,  low  cost,  easy  applicability  and  immediate 
results make VIA, VILI a useful screening test in developing countries like India. This 
must go hand in hand with increasing the awareness of women about cervical cancer 
screening programmes.
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PROFORMA
SERIAL NO.:
NAME 
AGE 
OP NO.
ADDRESS
RELIGION
OCCUPATION / INCOME
SOCIO ECONOMIC STATUS
MENSTRUAL HISTORY
AGE AT MENARCHE
CYCLE LENGTH
DURATION OF FLOW
AMOUNT OF FLOW
AGE AT MENOPAUSE
MARITAL HISTORY
MARRIED SINCE YEARS
AGE OF MARRIAGE 
SEXUAL HISTORY
AGE AT FIRST COITUS
FREQUENCY OF COITUS
NUMBER OF PARTNERS
OBSTETRIC HISTORY
PARITY 
LAST CHILD BIRTH
LACTATION
PERSONAL HISTORY
PID 
OC PILL INTAKE 
RT / CT / IMMUNO – SUPPRESSION
TB / DRUG INTAKE
COMPLAINTS
CLINICAL FINDINGS
DOWN STAGING
PAP SMEAR
VIA
VILI
COLPOSCOPY
COLPOSCOPY DIRECTED BIOPSY CERVIX 
IMPRESSION
MASTER CHART
S.
No. Name IP No. Age Mrd Yrs SEC Pty PC S/E Pap VIA VILI Colp Biop
1 Priya 21147 22 4 4 1 WD N I Neg Neg N NB
2 Kavitha 20460 25 6 4 2 WD N II Neg Neg N NB
3 Selvi 21146 28 10 4 2 LBA EC II Neg Neg N NB
4 Muniyammal 5709 27 15 5 3 WD EC II Pos Pos I CC
5 Ruth 22113 30 14 5 2 WD N III Pos Pos II CIN I
6 Lakshmi 14829 33 15 4 2 LBA N I Neg Neg N NB
7 Vasanthi 21071 30 12 4 1 LBA N I Neg Neg N NB
8 Uma 11522 30 17 4 1 WD N II Neg Neg N NB
9 Govindammal 14185 35 20 5 3 WD E III Pos Neg II CIN I
10 Malarvizhi 22215 37 20 5 4 WD E II Pos Pos I CC
11 Vani 8667 24 6 4 2 LAP N II Pos Neg N NB
12 Brinda 21285 29 10 4 2 LBA N II Neg Neg N NB
13 Ramani 8938 28 9 4 2 LBA N II Neg Neg I N
14 Devi 21285 42 26 5 2 WD E IV Pos Pos II CIN II
15 Geetha 8938 40 20 5 2 WD E IV Neg Pos II CIN II
16 Vadivu 21217 58 40 5 2 PCB E IV Pos Pos III SCC
17 Kanniammal 9217 42 24 5 2 PCB E IV Pos Pos III SCC
18 Sivabharathi 9250 30 16 4 3 WD E II Neg Pos II CIN I
19 Savitha 20627 40 20 4 3 WD E III Pos Pos II CIN I
20 Jamuna 23021 35 18 4 6 LBA N I Neg Neg N NB
21 Rajeswari 19350 40 21 4 2 LAP N I Neg Neg N NB
22 Umavathi 19351 29 13 4 3 LAP OCT II Neg Neg N NB
23 Begam 17824 60 44 5 8 WD E IV Pos Pos II SCC
S.
No. Name IP No. Age Mrd Yrs SEC Pty PC S/E Pap VIA VILI Colp Biop
24 Sarala 24567 32 16 5 3 WD H II Pos Pos I CIN I
25 Renuka 23360 25 11 4 3 LBA E I Neg Neg N NB
26 Murugammal 24720 45 27 4 2 WD N II Neg Neg N NB
27 Padma 22522 32 15 4 3 LAP N I Neg Neg N NB
28 Meharun 25474 38 21 5 5 WD E IV Pos Pos III CIN II
29 Rabitha 8527 55 40 4 4 LBA N I Neg Neg N NB
30 Selvarani 27193 36 17 4 2 LBA N I Neg Neg N NB
31 Badma 26071 23 5 4 1 WD N I Neg Neg N NB
32 Banu 27050 26 9 4 2 LAP E II Neg Pos N NB
33 Geetha 12641 28 10 4 2 LAP H II Neg Neg N NB
34 Rajee 28362 32 14 4 2 WD N II Neg Neg N NB
35 Rathna 29611 30 12 4 2 IMB P II Neg Pos N NB
36 Dhanam 29388 48 30 5 6 WD U III Pos Pos II SCC
37 Suriya 21971 32 14 4 3 WD H III Neg Neg I CC
38 Vasanthi 28355 45 23 4 2 LAP N I Neg Neg N NB
39 Mari 29501 25 7 4 2 LAP N I Neg Neg N NB
40 Saranya 30849 22 4 4 1 WD N I Neg Neg N NB
41 Suganya 30981 24 5 4 2 WD E II Neg Neg N NB
42 Marieswari 30193 30 12 4 3 LBA C III Neg Neg I CINI
43 Vijayalakshmi 31146 23 7 4 2 LBA E I Neg Neg N NB
44 Rani 29080 29 10 4 2 WD C II Neg Neg N NB
45 Pavithra 31247 26 9 4 2 WD EC II Pos Neg N NB
46 Hema 28562 30 9 4 2 LAP N II Neg Neg N NB
S.
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47 Kiliamma 31401 30 14 4 3 WD E II Neg Pos I CIN I
48 Anjali 27388 40 26 5 4 WD E III Pos Neg I CIN II
49 Ramani 32536 23 6 4 2 LBA E II Neg Neg N NB
50 Rukmani 30287 38 21 5 3 WD H III Pos Neg I CIN I
51 Shanthi 33724 37 20 4 2 LBA N I Neg Neg N NB
52 Rajakumari 28717 30 13 4 3 LAP N I Neg Neg N NB
53 Kaveri 26767 45 30 4 2 LBA N I Neg Neg N NB
54 Sarkunam 30808 40 21 5 4 WD H IV Pos Pos III CIN III
55 Lakshmi 40779 46 21 4 4 LBA OCT II Pos Neg N NB
56 Rani 40614 28 12 4 3 WD E II Neg Neg N NB
57 Manjula 40613 26 12 4 2 WD C II Pos Neg N NB
58 Lakshmi 40616 45 30 4 2 WD E II Pos Pos I CC
59 Mangalam 40560 25 8 4 2 WD N I Neg Neg N NB
60 Revathi 39129 27 11 4 3 LBA N I Neg Neg N NB
61 Kumutha 40739 29 12 4 3 LAP N I Neg Neg N NB
62 Vani 40763 26 9 4 2 WD N I Neg Neg N NB
63 Jeenath 40771 26 8 4 2 WD N I Neg Neg N NB
64 Mohana 40057 30 16 4 4 WD OCT III Pos Neg I CIN I
65 Mari 40756 30 14 4 2 WD N II Pos Pos N NB
66 Geetha 40785 32 16 4 2 LBA N I Neg Neg N NB
67 Muthu 40794 29 12 4 2 WD N II Neg Neg N NB
68 Kanchana 40778 28 10 4 2 LAP E II Pos Pos N NB
69 Usha 40798 26 6 4 2 LAP EC II Neg Neg N NB
S.
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70 Valliammal 41666 24 17 4 2 WD C I Neg Neg N NB
71 Suseela 41662 26 7 4 2 WD N I Neg Neg N NB
72 Muniyammal 41637 30 22 4 4 WD E III Pos Pos II CIN III
73 Durka 41650 30 12 4 2 WD E II Pos Pos N NB
74 Glory 41627 38 22 4 2 LBA N I Neg Neg N NB
75 Valarmathi 41663 30 13 4 2 WD N I Neg Neg N NB
76 Rekha 31048 28 10 4 1 WD C II Neg Neg N NB
77 Rahmath Bi 31136 60 45 5 6 WD E IV Pos Pos III SCC
78 Latha 31064 30 10 4 1 LAP N I Neg Neg N NB
79 Rajeswari 31708 40 26 4 3 WD E II Pos Pos N NB
80 Malika 32118 30 13 4 2 LBA N I Neg Neg N NB
81 Samanthi 32106 31 17 4 2 LBA N II Neg Neg N NB
82 Kamala 32113 24 6 4 2 WD N I Neg Neg N NB
83 Roja 30156 26 6 4 1 LAP E I Neg Neg N NB
84 Kaveri 41870 32 17 4 2 WD E III Pos Pos I CC
85 Dhanalakshmi 38923 40 32 4 3 WD N I Neg Neg N NB
86 Pavazha 42022 28 7 4 1 PCB P II Neg Neg N NB
87 Tamimunisha 42007 36 20 5 4 WD E II Neg Pos I CC
88 Ammu 31091 38 20 5 3 PCB U IV Pos Neg III SCC
89 Jyothi 42000 25 8 4 2 LAP N I Neg Neg N NB
90 Alamalu 33567 27 11 4 2 LAP N I Neg Neg N NB
91 Durga 40690 30 13 4 2 WD N II Neg Neg N NB
92 Meena 20011 25 6 4 2 LAP N II Neg Neg N NB
S.
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93 Oorvasi 42304 22 4 4 1 WD C I Neg Neg N NB
94 Kanaga 42132 29 10 4 2 IMB P II Neg Neg N NB
95 Amsa 42324 35 17 4 2 WD E III Pos Pos I CIN I
96 vijayalakshmi 42303 26 9 4 2 LAP N I Neg Neg N NB
97 Panchavarnam 42328 27 10 4 2 WD N I Neg Neg N NB
98 vijaya 46542 33 16 5 2 WD E II Pos Pos N NB
99 Seetha 42325 25 9 4 2 LAP N I Neg Neg N NB
100 Ambika 15798 29 12 4 3 LAP N I Neg Neg N NB
101 Jayanthi 15795 28 12 4 3 WD E II Pos Pos N NB
102 Komala 11755 26 10 4 2 LAP N I Neg Neg N NB
103 Jamuna 42375 32 15 4 2 WD EC II Neg Neg N NB
104 Parameswari 42309 34 18 4 3 WD E I Neg Neg N NB
105 Vanitha 42377 26 10 4 2 WD E II Pos Pos I CC
106 Kowsalya 42427 35 18 4 2 LAP H I Neg Neg N NB
107 Malika 42424 50 33 5 4 WD N IV Pos Pos III CIN II
108 Uma 42413 37 20 4 2 LAP N I Neg Neg N NB
109 Sujatha 42404 38 21 4 2 WD N II Neg Neg N NB
110 Lakshmi 32012 25 8 4 2 WD N I Neg Neg N NB
111 Govindammal 41614 28 10 4 2 WD E II Pos Pos I CC
112 Ammala 40806 28 12 4 2 WD N I Neg Neg N NB
113 Ponmathi 40827 29 12 4 3 WD E I Neg Neg N NB
114 Badmavathi 41689 33 15 4 2 WD EC II Neg Pos N NB
115 Devamani 42841 40 23 5 6 LAP C IV Pos Pos II CIN II
S.
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116 Gunasundari 41806 29 12 4 3 LAP H II Neg Neg N NB
117 Amudha 42646 25 7 4 2 WD N I Neg Neg N NB
118 Murugammal 32361 45 27 4 2 WD N II Neg Neg N NB
119 Padma 31668 32 15 4 3 LAP N I Neg Neg N NB
120 Gajalakshmi 42421 34 17 5 3 LAP OCT II Pos Neg N NB
121 Rani 41740 38 22 4 3 LAP N I Neg Neg N NB
122 Neelu 31688 30 13 4 2 WD N II Neg Neg N NB
123 Sariba 42634 39 22 4 2 WD E III Pos Pos I CC
124 Ameena 42834 44 28 4 3 WD N III Pos Neg II CIN II
125 Valli 42624 25 8 4 2 WD N I Neg Neg N NB
126 Sasikala 42515 32 16 4 2 LAP N II Neg Neg N NB
127 Mary 34228 36 20 5 4 LAP OCT IV Pos Pos II CIN II
128 Athilakshmi 35002 33 16 4 2 WD E II Neg Neg N NB
129 Vani 34929 36 9 4 2 WD N I Neg Neg N NB
130 Lakshmi 34262 35 18 4 3 LAP C II Pos Pos N NB
131 Govindalakshmi 32598 29 12 4 4 LAP N II Neg Neg N NB
132 Janaki 35708 26 8 4 2 WD N I Neg Neg N NB
133 Rasulbee 34211 27 11 4 2 LAP N I Neg Neg N NB
134 Kalaiselvi 34957 32 15 4 3 WD E II Pos Pos N NB
135 Allirani 36028 45 28 4 3 WD N I Neg Neg N NB
136 Maheswari 35412 45 27 4 3 LAP OCT II Neg Neg N NB
137 Maragatham 31634 42 25 4 2 LBA H II Neg Pos N NB
138 Sasikala 29132 36 19 4 2 WD N I Neg Neg N NB
S.
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139 Rani 33989 55 38 5 5 WD N IV Pos Neg III CIN III
140 Mallika 35682 29 7 4 2 WD N I Neg Neg N NB
141 Amaravathi 36477 45 27 4 3 LAP E II Pos Pos I CC
142 Vasanthi 35811 49 31 4 4 LAP N II Neg Neg N NB
143 Nirmala 36509 27 10 4 2 WD N I Neg Neg N NB
144 Ponnammal 34383 30 12 4 3 WD H II Neg Neg N NB
145 Parimala 31702 37 20 4 2 WD E II Neg Pos I CIN I
146 Shanmugavalli 37635 28 11 4 2 LAP N I Neg Neg N NB
147 Jasmine 33984 30 12 4 3 LAP N II Neg Neg N NB
148 Meena 37111 33 15 4 2 WD E II Pos Neg N NB
149 Suguna 38693 25 8 4 1 WD N I Neg Neg N NB
150 Kasiammal 37187 35 17 4 2 LAP N II Neg Neg N NB
151 Revathi 39530 28 10 4 2 WD N I Neg Neg N NB
152 Saraswathi 37924 26 9 4 2 WD N I Neg Neg N NB
153 Puspa 35469 28 11 4 3 LAP N II Neg Neg N NB
154 Dhanalakshmi 38465 45 27 5 6 WD E III Neg Pos II CIN II
155 Devi 38573 35 8 4 2 WD N I Neg Neg N NB
156 Nirmala 39238 31 14 4 3 LAP N I Neg Neg N NB
157 Muniammal 35118 27 10 4 2 WD N I Neg Neg N NB
158 Valliammal 38979 39 23 5 4 LAP N III Pos Neg I CIN I
159 Jayanthi 34309 26 9 4 2 LAP N I Neg Neg N NB
160 Nirmala 34635 29 12 4 3 LAP N II Neg Neg N NB
161 Meenatchi 34183 25 8 4 2 WD N I Neg Neg N NB
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162 Durga 41470 28 11 4 3 WD E II Pos Pos I CC
163 Saraswathi 41424 32 16 4 2 WD E I Neg Neg N NB
164 Kamatchi 40487 28 11 4 1 LAP N I Neg Neg N NB
165 Nagammal 40894 45 30 5 3 LAP N II Pos Pos I CC
166 Vimala 30115 31 15 4 3 WD N I Neg Neg N NB
167 Gowri 40479 25 8 4 2 WD E I Neg Neg N NB
168 Lakshmi 40453 35 15 4 3 WD H II Neg Pos N NB
169 Varalakshmi 38966 40 21 4 2 WD N I Neg Neg N NB
170 Inbarani 411374 48 33 4 3 WD E III Pos Pos I CC
171 Vijaya 40629 24 8 4 2 WD C I Neg Neg N NB
172 Fathima 39681 52 35 4 3 WD N III Pos Neg II CIN II
173 Samburanam 40468 26 9 4 2 LAP N I Neg Neg N NB
174 Valli 27497 34 18 4 2 WD E I Neg Neg N NB
175 Jyothi 37187 28 10 4 1 LAP N I Neg Neg N NB
176 Sengala 39530 35 18 4 3 WD E II Pos Pos N NB
177
Palanimamma
l 37924 31 14 4 2 WD N I Neg Neg N NB
178 Kamatchi 35469 46 30 4 1 WD N II Pos Neg N NB
179 Akila 38475 30 11 4 2 LAP N I Neg Neg N NB
180 Lakshmi 38573 28 10 4 2 WD E II Neg Neg N NB
181 Sagayamary 39238 32 15 5 3 PCB E III Pos Pos I CIN I
182 Kirandevi 35118 35 18 4 3 WD E II Pos Neg I CC
183 Nagammaal 38979 50 32 4 3 LAP N I Neg Neg N NB
184 Susila 34039 42 24 4 6 WD N IV Pos Pos II CIN II
S.
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185 Vijaya 34635 37 20 4 4 WD OCT I Neg Neg N NB
186 Kavitha 34183 27 9 4 2 WD N II Neg Neg N NB
187 Suvathi 41470 27 10 4 3 LAP N I Neg Neg N NB
188 Lalitha 41424 29 11 4 4 WD E II Pos Pos I CC
189 Kamatchi 40487 35 17 4 2 WD E III Pos Neg I N
190 Varalakshmi 40894 26 10 4 2 WD E I Neg Neg N NB
191 Suganthi 30115 26 8 4 3 WD N I Neg Neg N NB
192 Kanagavalli 40479 44 26 5 5 WD E II Neg Neg I CIN I
193 Shanthi 40452 40 24 4 3 WD E I Neg Neg N NB
194 Saratha 38966 38 20 4 2 LAP N I Neg Neg N NB
195 Nasima 41374 35 20 5 3 WD N II Pos Pos N NB
196 Kumutha 40629 32 15 4 3 LAP N I Neg Neg N NB
197 Savithri 39681 35 20 4 2 IMB E III Pos Pos I CIN I
198 Girija 40468 28 10 4 3 WD N I Neg Neg N NB
199 Pappa 27497 26 8 4 2 WD N I Neg Neg N NB
200 Punithavathi 27442 43 25 4 3 WD E II Pos Pos I CIN I
201 Suganthi 41236 34 18 4 2 LAP N I Neg Neg N NB
202 Sasikala 41502 31 14 4 2 WD N I Neg Neg N NB
203 Mala 41413 28 10 4 2 WD N I Neg Neg N NB
204 Kamala 34873 38 21 5 5 PCB E III Neg Pos II CIN II
205 Selvi 31972 26 8 4 2 LAP N I Neg Neg N NB
206 Amutha 31960 37 19 4 1 WD N I Neg Neg N NB
207 Manjula 40165 28 11 4 2 WD N II Neg Neg N NB
S.
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208 Karpagam 40334 30 11 4 2 LAP N II Neg Neg N NB
209 Kavitha 13176 27 7 4 1 WD N I Neg Neg N NB
210 Vijaya 41838 35 16 4 3 WD E III Neg Neg I CIN I
211 Rani 46132 32 14 4 3 WD E II Neg Pos N NB
212 Jayasudha 45302 26 8 4 2 LAP N I Neg Neg N NB
213 Dhatchayani 37820 39 20 4 3 WD N II Neg Neg N NB
214 Kalapana 42037 28 10 4 2 WD E I Neg Neg N NB
215 Sublakshmi 41945 42 22 4 2 WD E II Neg Neg N NB
216 Lakshmi 43792 38 20 4 3 LAP N II Neg Neg N NB
217 Fathima 36619 37 18 4 2 WD C I Neg Neg N NB
218 Jaya 36655 40 25 5 4 WD E IV Pos Pos II CIN II
219 Devaki 34309 29 12 4 2 WD E II Neg Neg N NB
220 Vijaya 35248 42 25 4 3 WD H II Pos Pos I CIN I
221 Padma 47134 25 6 4 2 WD N I Neg Neg N NB
222 Valli 44923 34 17 4 2 WD C I Neg Neg N NB
223 Uma 47515 26 7 4 2 WD N I Neg Neg N NB
224 Karpagam 38202 32 17 5 2 WD E III Pos Neg II CIN II
225 Ambika 39139 30 13 4 2 LAP N I Neg Neg N NB
226 Roopa 30185 22 4 4 1 LAP N I Neg Neg N NB
227 Suseela 36989 36 19 4 2 WD E II Neg Neg N NB
228 Sangeetha 45630 28 9 4 2 PCB E II Neg Pos N NB
229 Archana 24737 23 3 4 1 LBA N I Neg Neg N NB
230 Ayesha 43208 33 18 4 3 WD E II Neg Neg N NB
S.
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231 Rubela 42366 44 25 4 4 WD N III Pos Neg II CIN I
232 Punitha 40588 29 9 4 2 LBA N I Neg Neg N NB
233 Ganga 42603 21 3 4 1 WD N I Neg Neg N NB
234 Seetha 41118 27 9 4 2 WD E II Neg Neg N NB
235 Rajakumari 12917 25 8 4 1 LBA N I Neg Neg N NB
236 Arya 13382 32 15 4 2 LAP N II Neg Neg N NB
237 Varalakshmi 9396 24 6 4 2 WD N I Neg Neg N NB
238 Jyothi 12196 40 26 4 2 WD H III Pos Pos II CIN II
239 Rajathi 11625 37 20 4 2 LBA N I Neg Neg N NB
240 Indrani 42500 34 17 4 3 WD E II Neg Neg N NB
241 Maheswari 13116 30 12 4 2 LBA EC I Neg Neg N NB
242 Parimala 36231 25 4 4 2 WD N I Neg Neg N NB
243 Vijaya 33724 35 15 4 2 WD N II Pos Neg N NB
244 Vedavalli 15373 37 20 4 2 WD E II Neg Neg N NB
245 Manjula 24590 22 4 4 2 WD N I Neg Neg N NB
246 Kothai 26469 30 12 4 2 WD N II Neg Neg N NB
247 Savithri 17113 38 23 5 3 WD H III Pos Pos II CIN I
248 Athilakshmi 17099 45 30 5 3 WD N II Pos Pos N NB
249 Latha 18007 35 15 4 2 WD E II Pos Neg N NB
250 Prema 17101 32 12 4 2 WD E II Neg Neg N NB
251 Karpagam 16206 30 15 5 3 WD H III Pos Pos I CIN I
252 Kannagi 17598 34 15 4 1 WD N II Neg Pos N NB
253 Sundari 12865 40 25 4 2 WD E II Pos Neg II CIN I
S.
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254 Deepa 12522 25 6 4 2 LAP N I Neg Neg N NB
255 Ranjitham 17922 36 20 4 2 LAP N II Neg Neg N NB
256 Pramila 38988 35 17 4 2 WD N II Neg Neg N NB
257 Kumutha 18228 31 11 4 1 LBA N I Neg Neg N NB
258 Meena 16686 33 12 4 2 WD E II Pos Pos N NB
259 Mehrunisha 38511 29 12 4 2 WD E II Pos Neg N NB
260 Murugammal 19049 30 13 4 2 WD N II Neg Neg N NB
261 Santhi 25699 43 25 4 2 LBA N III Pos Pos I N
262 Senthamarai 17052 28 8 4 2 LAP N I Neg Neg N NB
263 Athilakshmi 19385 51 35 4 2 LAP N III Pos Pos I CIN I
264 Rukmani 19722 40 22 4 2 WD E II Pos Pos I N
265 Annalakshmi 18454 25 7 4 1 WD E I Neg Neg N NB
266 Salamma 19317 55 40 5 3 WD E IV Pos Pos III SCC
267 Yasmin 19786 35 20 4 3 WD N I Neg Neg N NB
268 Rajeswari 20460 32 17 4 2 LAP H II Pos Pos N NB
269 Mary 21124 45 26 4 4 WD H II Pos Pos I CC
270 Sundari 21129 30 14 4 2 LAP H II Neg Neg N NB
271 Bavani 20640 32 15 4 2 WD H II Pos Pos I N
272 Priya 17959 24 5 4 1 LAP N I Neg Neg N NB
273 Ramya 21315 27 8 4 2 WD EC I Neg Neg N NB
274 Aarthy 17430 23 5 4 2 WD N I Neg Neg N NB
275 Annammal 29833 60 42 5 5 WD N III Pos Pos I CIN II
276 Santhanalakshmi 18733 36 15 4 3 IMB H II Neg Pos II CIN I
S.
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277 Agavalli 18235 28 8 4 2 LAP N I Neg Neg N NB
278 Mumthaj 11764 36 19 4 2 WD H II Neg Neg N NB
279 Geetha 16454 30 9 4 2 WD N I Neg Neg N NB
280 Komala 11517 26 5 4 1 WD H II Pos Pos N NB
281 Fathima 16527 33 11 4 3 WD N I Neg Neg N NB
282 Santhi 16494 41 25 4 2 WD H III Neg Neg I CIN I
283 Kalyani 27328 45 30 4 3 IMB H III Neg Pos I CIN I
284 Chellamai 13844 51 35 4 3 WD N II Pos Neg II CIN I
285 Periyanayagi 22972 35 19 4 2 LAP EC II Pos Pos I N
286 Sujatha 24332 42 26 4 2 WD N II Pos Pos I N
287 Puvitha 25534 29 15 4 2 WD N II Neg Neg N NB
288 Rajeswari 23178 28 10 4 2 WD N I Neg Neg N NB
289 Jaya 22473 40 25 4 2 LBA N II Pos Pos I CC
290 Lakshmi 23289 22 4 4 2 WD N II Pos Neg N NB
291 Kala 22473 40 15 4 3 WD N III Pos Pos II CIN I
292 Selvi 28152 31 9 4 2 WD EC II Neg Neg N NB
293 Chitra 23952 25 7 4 2 WD N I Neg Neg N NB
294 Pooja 21045 26 7 4 2 WD E I Neg Neg N NB
295 Bhoopathi 44793 24 6 4 2 LAP E I Neg Neg N NB
296 Dhatchayini 22337 25 6 4 2 WD E II Pos Neg N NB
297 Vanitha 23579 27 10 4 2 WD E III Pos Pos I CIN I
298 Deepa 23370 24 7 4 2 WD N II Neg Pos N NB
299 Meenatchi 23479 32 4 4 2 WD E I Neg Neg N NB
S.
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300 Padmavathi 23501 30 15 4 3 WD N III Neg Pos II CIN II
301 Ravanammal 22560 30 14 4 2 LAP EC II Neg Neg N NB
302 Lavanya 42891 28 7 4 2 LBA EC I Neg Neg N NB
303 Malliga 42851 36 13 4 2 WD N I Neg Neg N NB
304 Ruth 42628 42 24 4 2 WD E II Pos Pos I CC
305 Fathima be 24200 35 20 4 2 WD E II Neg Neg N NB
306 Parvathi 45843 44 30 4 2 LBA N I Neg Neg N NB
307 Banu 24341 26 9 4 2 WD C I Neg Neg N NB
308 Kannagi 41749 30 13 4 3 LAP E I Neg Neg N NB
309 Pachiamma 46569 47 27 4 3 LBA H IV Pos Pos III CIN III
310 Uma 46615 26 8 4 3 WD N I Neg Neg N NB
311 Kalaivani 43094 28 7 4 1 WD E I Neg Neg N NB
312 Lakshmi 44366 26 7 4 2 WD N I Neg Neg N NB
313 Rani 42863 37 20 4 3 WD E III Neg Pos II CIN II
314 Thulasi 25734 37 20 5 4 WD E III Pos Pos II CIN I
315 Selvi 42526 35 15 4 2 LBA N I Neg Neg N NB
316 Shanthi 44175 33 20 5 3 WD N I Neg Neg N NB
317 Devi 41946 25 7 4 2 WD N I Neg Neg N NB
318 Nagarathinam 43944 46 30 5 4 WD C III Pos Pos I CIN I
319 Jagatha 30659 32 15 4 4 LBA H II Pos Pos I N
320 Santha 16921 36 13 4 2 LBA N I Neg Neg N NB
321 Puspa 43094 26 8 4 2 WD N I Neg Neg N NB
322 Saraswathi 39643 30 9 4 1 WD N I Neg Neg N NB
S.
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323 Prema 43053 30 13 4 2 WD H III Pos Pos I CIN I
324 Mariamma 38081 32 18 4 2 WD N I Neg Neg N NB
325 Fathima 31625 23 5 44 2 WD N I Neg Neg N NB
326 Prabavathi 43220 30 14 4 3 WD E II Pos Pos I CC
327 Meenatchi 43160 30 15 4 2 WD N I Neg Neg N NB
328 Shanthi 43168 37 20 4 3 WD N II Neg Neg I CIN I
329 Prabhavathi 14653 30 14 4 3 WD N I Neg Neg N NB
330 Arasi 42325 36 15 4 2 LBA N I Neg Neg N NB
331 Suseela 42240 35 15 4 4 WD E II Pos Pos I N
332 Geetha 43014 30 12 4 2 WD N I Neg Neg N NB
333 Muthulakshmi 42309 57 40 4 5 WD E IV Pos Pos II CIN II
334 Komala 45001 23 4 4 1 WD N I Neg Neg N NB
335 Lakshmi 42000 50 30 4 6 WD U IV Pos Pos III CIN III
336 Kasdoori 31091 36 20 4 2 WD N I Neg Neg N NB
337 Malathi 42023 36 19 4 2 WD E I Neg Neg N NB
338 Anitha 41806 30 8 4 2 WD H III Pos Pos I CC
339 Marry 30901 42 17 4 3 WD H III Pos Pos II CIN I
340 Lalitha 42200 56 20 4 2 WD N I Neg Neg N NB
341 Nagavalli 15609 38 17 4 2 WD N II Pos Pos N NB
342 Rajakumari 41627 32 13 4 3 LAP N I Neg Neg N NB
343 Gandhimathi 40051 48 26 4 3 WD E I Neg Neg N NB
344 Devi 41662 28 12 4 2 WD C II Neg Neg N NB
345 Valli 41374 35 19 4 3 WD N II Pos Pos I CIN I
S.
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346 Vijaya 19175 33 16 4 2 WD E II Pos Pos N NB
347 Malarvizhi 20011 50 30 4 3 WD N I Neg Neg N NB
348 Ragavi 40559 25 7 4 2 LAP N I Neg Neg N NB
349 Bakkiam 45590 23 4 4 2 WD N I Neg Neg N NB
350 Mary 43269 43 23 4 2 WD E II Pos Neg N NB
351 Thilagavathi 33087 30 14 4 3 WD E III Neg Pos II CIN I
352 Kala 38750 25 8 4 2 WD C I Neg Neg N NB
353 Kavitha 38021 28 11 4 3 WD N II Neg Neg N NB
354 Devi 37953 30 11 4 2 LAP N I Neg Neg N NB
355 Maha 38634 35 15 4 3 LBA EC I Neg Neg N NB
356 Padma 38082 40 24 4 2 LBA N I Neg Neg N NB
357 Sathya 22653 50 30 4 3 WD OCT III Neg Neg I CIN I
358 Amala 14978 35 19 4 3 LAP N II Neg Neg N NB
359 Saroja 13627 35 13 4 2 WD P I Neg Neg N NB
360 Suguna 38292 32 16 5 5 WD OCT II Neg Pos N NB
361 Chandra 32305 40 22 4 4 LBA E II Pos Pos I CC
362 Anjali 14024 26 8 4 2 LAP N I Neg Neg N NB
363 Muthulakshmi 12660 38 16 4 2 LAP N I Neg Neg N NB
364 Maheswari 12152 45 25 4 4 WD N III Pos Pos I CIN I
365 Kasthuri 12193 40 18 4 3 LAP OCT I Neg Neg N NB
366 Meera 10969 35 10 4 2 WD N I Neg Neg N NB
367 Amaravathi 32370 45 27 4 3 WD E II Pos Pos I CC
368 Victoria 26033 47 30 4 4 LAP EC II Neg Neg N NB
S.
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369 Marry 27879 45 25 5 4 WD H III Pos Neg II CIN II
370 Sasikala 10600 26 6 4 2 WD N I Neg Neg N NB
371 Reena 19486 32 15 4 2 WD E I Neg Neg N NB
372 Saraswathi 27164 40 25 4 2 WD N II Neg Neg N NB
373 Savithri 27151 40 24 4 3 PCB E IV Pos Pos II CIN II
374 Latha 22598 24 4 4 2 WD N I Neg Neg N NB
375 Rani 17982 28 9 4 2 WD C I Neg Neg N NB
376 Sujatha 22964 38 20 5 2 LBA E II Neg Neg N NB
377 Padmavathi 20332 27 8 4 2 WD N I Neg Neg N NB
378 Malliga 22182 29 10 4 1 IMB P II Neg Neg N NB
379 Egavalli 41565 37 20 4 3 WD E II Pos Pos N NB
380 Meenatchi 20561 28 11 4 2 WD N I Neg Neg N NB
381 Thanam 28108 48 30 4 3 LAP OCT II Pos Neg N NB
382 Jeyanthi 20180 33 12 5 3 WD E I Neg Neg N NB
383 Meena 14172 36 20 4 2 WD H II Pos Pos I CC
384 Thilothama 40817 26 8 4 2 WD N I Neg Neg N NB
385 Suguna 40823 37 22 4 3 LAP N III Pos Pos I CIN I
386 Radha 41234 28 10 4 2 LAP N I Neg Neg N NB
387 Sumathi 41362 30 12 5 3 WD E II Pos Pos I CC
388 Yasodha 18200 30 13 4 3 WD N I Neg Neg N NB
389 Kasthoori 23322 40 21 4 1 WD N I Neg Neg N NB
390 Komala 21254 22 6 4 2 WD E II Neg Pos N NB
391 Latha 23952 36 20 4 2 LBA C II Neg Neg N NB
S.
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392 Prabavathi 22641 42 17 5 2 LAP N I Neg Neg N NB
393 Chitra 26057 25 10 5 3 WD N I Neg Neg N NB
394 Rajeswari 25732 34 18 5 3 WD H II Neg Neg I CIN I
395 Nirmala 26273 48 30 5 6 WD E II Neg Neg N NB
396 Mangai 25919 46 30 4 2 LBA EC I Neg Neg N NB
397 Varalakshmi 22903 40 20 5 2 WD E II Pos Pos II CC
398 Parveen 26761 35 19 5 4 WD EC II Neg Neg N NB
399 Kumari 21231 25 4 4 2 WD N I Neg Neg N NB
400 Jaya 25784 40 25 4 2 LAP N II Neg Neg N NB
401 Jayamma 22598 35 10 4 2 LAP N I Neg Neg N NB
402 Kumari 12440 24 7 4 2 WD N I Neg Neg N NB
403 Sarasu 24132 27 6 4 2 LBA C II Neg Neg N NB
404 Parameswari 27330 40 21 4 2 LBA EC I Neg Neg N NB
405 Kalai 22646 42 23 5 5 WD E III Pos Neg II CIN I
406 Ramani 13387 38 12 4 2 WD N II Neg Pos II CIN I
407 Nagammaal 27591 28 8 4 2 LAP N II Pos Neg N NB
408 Shantha 37591 35 17 4 3 LBA EC I Neg Neg N NB
409 Stella 37850 28 6 4 2 WD N I Neg Neg N NB
410 Thilagavathi 31856 38 20 4 3 WD E II Neg Neg N NB
411 Rajeswari 37953 45 30 5 5 WD E IV Pos Pos III CIN III
412 Indhira 37903 23 5 4 2 WD N I Neg Neg N NB
413 Shanthi 37512 27 8 4 2 WD E I Neg Neg N NB
414 Rajee 37706 45 24 4 2 WD N II Neg Neg N NB
S.
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415 Valli 37656 55 40 5 4 WD U IV Pos Pos III CIN III
416 Marry 37710 36 16 4 4 WD N II Neg Neg N NB
417 Nageswari 37645 32 15 4 2 WD P II Neg Pos N NB
418 Vani 38225 38 20 5 5 WD E III Pos Pos I CC
419 Selvi 38272 28 10 4 3 WD E II Neg Neg N NB
420 Thanam 16002 30 14 4 2 LAP N I Neg Neg N NB
421 Kasthoori 17780 35 15 4 3 WD H II Neg Neg N NB
422 Ellammal 25425 23 4 4 1 LAP N I Neg Neg N NB
423 Nirmala 22564 40 25 4 3 WD N I Neg Neg N NB
424 Lakshmi 13922 30 11 4 2 LBA N I Neg Neg N NB
425 Uma 25194 26 5 4 1 WD N II Neg Neg N NB
426 Vasanthi 28563 34 18 4 2 WD E III Pos Pos II CIN I
427 Shanthi 12211 30 12 4 2 LAP N II Pos Neg N NB
428 Ranganayagi 23975 32 10 4 3 LBA N II Neg Pos N NB
429 Thagira 23897 30 12 4 2 WD N II Neg Neg N NB
430 Gayathri 23695 28 10 4 2 WD N II Pos Neg N NB
431 Jamuna 32305 32 15 4 2 WD N I Neg Neg N NB
432 Shanthi 27164 26 6 4 2 LAP N I Neg Neg N NB
433 Vijaya 22964 42 23 4 3 WD N III Pos Neg II CIN I
434 Mahalakshmi 30659 30 15 4 2 WD N II Pos Neg N NB
435 Roja 39675 21 3 4 1 LAP N II Neg Neg N NB
436 Shankari 33478 38 22 5 5 WD E II Neg Neg N NB
437 Latha 32170 38 20 4 2 WD E III Pos Pos I CIN I
S.
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438 Selvi 32790 39 23 4 3 WD C II Pos Neg N NB
439 Vijayalakshmi 23367 30 9 4 2 LAP N I Neg Neg N NB
440 Yasodha 25693 30 8 4 2 LAP E II Neg Neg N NB
441 Allirani 17998 40 23 4 3 WD EC II Pos Pos I CC
442 Jyothi 23121 23 6 4 2 WD E I Neg Neg N NB
443 Mohana 24753 30 14 4 2 LAP N II Neg Neg N NB
444 Malar 43213 28 10 4 2 WD E II Neg Neg N NB
445 Thangam 42569 28 10 4 2 LAP N I Neg Neg N NB
446 Maha 43511 33 15 4 2 WD E II Neg Neg N NB
447 Nabeesha 28977 25 6 4 1 WD N II Neg Pos N NB
448 Chellammal 32667 28 10 5 2 WD P II Neg Neg N NB
449 Vanaja 46677 38 18 4 2 WD N II Neg Pos II CIN I
450 Beevi 45534 28 10 4 4 LBA H II Pos Pos I CC
451 kannagi 40700 28 7 4 1 WD E I Neg Neg N NB
452 Shanthi 41872 35 15 5 2 LBA N I Neg Neg N NB
453 Poovitha 32413 24 7 4 2 WD N II Neg Neg N NB
454 Kanchana 37834 28 10 4 2 WD N II Neg Pos N NB
455 Anandavalli 22561 28 13 5 4 WD H III Pos Neg I CIN I
456 Rani 46611 28 9 4 2 WD C I Neg Neg N NB
457 Parimala 23423 25 4 4 2 WD N I Neg Neg N NB
458 Kalai 43268 28 7 4 1 WD E I Neg Neg N NB
459 Manju 38750 25 7 4 1 WD N I Neg Neg N NB
460 Kavitha 37953 22 4 4 1 LBA N II Neg Neg N NB
S.
No. Name IP No. Age Mrd Yrs SEC Pty PC S/E Pap VIA VILI Colp Biop
461 Amirtham 42981 34 17 4 2 WD E III Pos Neg II CIN I
462 Lavanya 23844 24 7 4 2 LAP EC I Neg Neg N NB
463 Rathna 23178 26 10 4 2 LBA N I Neg Neg N NB
464 Pratheepa 43273 32 14 5 2 WD E II Neg Neg N NB
465 Malarkodi 29722 33 15 4 2 WD E II Neg Pos N NB
466 Ramya 20466 27 10 4 2 WD N I Neg Neg N NB
467 Savitha 22141 35 19 4 4 WD EC II Neg Neg N NB
468 Kumari 21937 25 4 4 2 WD N I Neg Neg N NB
469 Jayamma 17114 35 10 4 2 LAP N I Neg Neg N NB
470 Kanaga 17598 34 18 5 3 WD H III Neg Pos I CIN I
471 Latha 28988 24 4 4 2 WD N I Neg Neg N NB
472 Padmavathi 29049 27 8 4 2 LAP N I Neg Neg N NB
473 Rajathi 45637 37 20 4 2 LBA N I Neg Neg N NB
474 Indrani 40833 34 17 4 3 WD E II Neg Neg N NB
475 Maheswari 22178 30 12 4 2 LBA EC I Neg Neg N NB
476 Parimala 42356 25 4 4 2 WD N I Neg Neg N NB
477 Vijaya 20647 35 15 4 2 WD N II Neg Neg N NB
478 Vedavalli 38512 37 20 4 2 WD E II Neg Neg I N
479 Manjula 28988 22 4 4 2 WD N I Neg Neg I N
480 Kothai 37922 30 12 4 2 WD N II Neg Neg I N
482 Rabitha 31711 55 40 4 4 LBA N I Neg Neg I N
483 Selvarani 26469 36 17 4 2 LBA N I Neg Neg I N
S.
No. Name IP No. Age Mrd Yrs SEC Pty PC S/E Pap VIA VILI Colp Biop
484 Badma 22182 23 5 4 1 WD N I Neg Neg I N
485 Banu 20332 26 9 4 2 LAP E II Neg Neg I N
486 Geetha 31092 28 10 4 2 LAP H II Neg Neg I N
487 Rajee 45008 32 14 4 2 WD N II Neg Neg I N
488 Rathna 46569 30 12 4 2 IMB P II Neg Neg I N
489 Kala 41749 45 25 5 3 WD N III Neg Neg III CIN I
490 Devi 22457 29 13 4 2 WD E II Neg Pos II CIN I
491 Lalitha 31934 56 20 4 2 WD N I Neg Neg I N
492 Nagavalli 41121 38 17 4 2 WD N II Neg Neg I N
493 Rajakumari 40088 32 13 4 3 LAP N I Neg Neg I N
494 Gandhimathi 41098 48 26 4 3 WD E I Neg Neg I N
495 Devi 34532 28 12 4 2 WD C II Neg Neg I N
496 Rajathi 41338 37 20 4 2 LBA N I Neg Neg I N
497 Indrani 42578 34 17 4 3 WD E II Neg Neg I N
498 Maheswari 48923 30 12 4 2 LBA EC I Neg Neg I N
499 Parimala 32338 25 4 4 2 WD N I Neg Neg I N
500 Vijaya 35987 35 15 4 2 WD N II Neg Neg I N
KEY WORDS TO MASTER CHART
Mrd Yrs = Married Years Duration
PC = Presenting Complaint
Biop = Biopsy
Colp = Colposcopy
Pty = Parity
WD = White Discharge
LAP = Lower Abdominal Pain
LBA = Low Backache
IMB = Inter Menstrual Bleed
PCB = Post Coital Bleed
N = Normal
E = Erosion
EC = Ectropion
H = Hypertrophy
OCT = Old Cervical Tear
P = Polyp  
 
U = Ulcer  
 
C = Congestion  
 
NB = No Biopsy  
 
CC = Chronic Cervicitis  
 
SCC = Squamous Cell Carcinoma
